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1. ABSTRACT 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Moreover, 
ischemic heart diseases account for most CVDs-related deaths and, alone, are the leading 
cause of death worldwide. These conditions often lead to acute myocardial infarction (MI) that 
involves ischemia-induced cardiomyocyte (CM) death and the formation of a non-functional 
scar tissue at the infarcted site, greatly impairing cardiac function, often leading to heart failure. 
Moreover, this collagen-rich scar tissue lacks electrical conductivity which often promotes the 
occurrence of arrhythmias in a scenario of MI due to the disruption of electrical conduction. 
Hence, in heart failure ventricular tachyarrhythmia (increased heart rate) and fibrillations 
(disorganized action potential (AP) propagation in the myocardium) are common events. 
Attempting to surpass the shortcomings of current gold-standard therapies, novel therapies, 
involving gene and/or cell therapy or tissue engineering have been emerging. Most of these 
therapies focus on improving cardiac function, reducing cardiac remodeling and/or are 
dedicated to restore cardiac electrical integrity. However, in vivo studies assessing therapeutic 
alternatives that promote concurrent contractile and electrical functional repair are scarce. 
Piezoelectric materials exhibit an electric polarization (and a resultant electrical 
activity) upon mechanical stress (direct effect) or vice-versa (converse effect). Since the heart 
exhibits robust cyclic movements, the implantation of these materials on an injured 
myocardium holds great potential as could be possible to obtain a sustainable electrical 
activity, induced by native mechanical stimuli, with a consequent improvement of 
electromechanical integration and cardiac function. In vitro experiments have shown that thin 
films of polycaprolactone (PCL) covered in polyvinylidene fluoride–trifluoroethylene (PVDF-
TrFE) piezoelectric fibers, maintained contractility and viability of cardiomyocytes in vitro, 
inducing their alignment, improved intercellular coupling, increased ionic channel expression 
and calcium handling. In line with these experiments the herein work aims to test the 
xvi 
  
therapeutic potential of these materials for the treatment of MI. For that purpose, these films 
(herein referred as “Piezo patches”) were implanted in the hearts of mice subjected to MI. One 
month after implantation, functional and histological characterization were performed. The 
materials induced an exacerbated inflammatory reaction associated with multinuclear 
inflammatory cells, resembling a foreign body reaction. Furthermore, although no significant 
differences were observed concerning echocardiographic analysis and cardiac remodeling, a 
consistent tendency for improvement was observed in the Piezo patch-treated animals. Of 
note, electrocardiograms showed that the materials piezoelectric fibers resulted in enhanced 
myocardial conduction with evidences of having a reduced susceptibility to suffer ventricular 
arrhythmia events, when compared with films containing non-conductive, polycaprolactone 
(PCL) fibers. Thus, the herein work support the use piezoelectric materials as tissue 
engineering conductive scaffolds and/or to be used in combination with other therapies 
towards improvement of electrical integrity following MI.  
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2. SUMÁRIO 
As doenças cardiovasculares são a principal causa de morte no mundo. Entre estas, 
o enfarte agudo do miocárdio caracteriza-se pela morte de tecido viável e subsequente 
remodelagem cardíaca, onde há deposição de tecido cicatricial que prejudica a função do 
miocárdio e pode originar falência cardíaca. Esta cicatriz, rica em colagénio, tem fracas 
propriedades condutoras, promovendo frequentemente a ocorrência de arritmias devido à 
disrupção elétrica no miocárdio. Assim, em contexto de falência cardíaca é comum ocorrerem 
taquiarritmias ventriculares (ritmo cardíaco aumentado) e fibrilações. Numa tentativa de 
ultrapassar as limitações das terapias convencionais, têm surgido novas abordagens 
terapêuticas que procuraram melhorar a função e reduzir a remodelagem cardíaca ou 
restaurar a integridade elétrica do coração. No entanto, presentemente existem muito poucos 
estudos que avaliem in vivo novas terapias para melhorar simultaneamente a função contráctil 
e eléctrica. 
Os materiais piezoelétricos exibem uma polarização elétrica (e, consequentemente, 
atividade elétrica) aquando da deformação mecânica (efeito direto) ou vice-versa (efeito 
inverso). Uma vez que o coração apresenta movimentos cíclicos robustos, a implantação 
destes materiais num miocárdio com lesão constitui uma alternativa com elevado potencial 
uma vez que possibilitaria obter atividade elétrica sustentável, induzida pelo estímulo 
mecânico nativo, com uma subsequente melhoria na integração eletromecânica e função 
cardíaca. 
Experiências in vitro mostraram que filmes finos de policaprolactona contendo fibras 
de fluoreto de polivinilideno – trifluoroetileno (polímero com propriedades piezoelétricas) 
depositadas no topo, mantiveram eficazmente a contractilidade e viabilidade de 
cardiomiócitos, promovendo o seu alinhamento, melhorando o acoplamento intercelular, 
aumentando a expressão de determinados canais iónicos e regularizando os níveis de cálcio. 
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No seguimento das experiências descritas, o trabalho efetuado no contexto da 
presente tese consistiu em avaliar o potencial terapêutico destes materiais no tratamento do 
enfarte do miocárdio. Para esse efeito, os materiais foram implantados em coração de 
murganhos que foram submetidos a indução cirúrgica de enfarte do miocárdio. Um mês após 
implantação, os animais foram caracterizados ao nível histológico e funcional. Os materiais 
piezoelétricos induziram uma reação inflamatória com abundantes células inflamatórias 
multinucleares, à semelhança do que ocorre nas reações de corpo estranho. Adicionalmente, 
apesar de não se terem observado diferenças estatisticamente significativas na função 
contrátil e na remodelagem cardíaca, os diferentes parâmetros indicam uma melhoria ligeira 
do grupo implantado com fibras piezoeléctrica. Por electrocardiograma mostrou-se que as 
fibras piezoelétricas depositadas no miocárdio promoveram uma melhoria significativa da 
condução do miocárdio em comparação com filmes contendo fibras (não-condutoras) de 
policaprolactona. 
Em suma, o presente trabalho revela que os materiais piezoelétricos utilizados 
poderão ter potencial como uma alternativa na engenharia de tecido cardíaco e/ou serem 
usados em combinação com outras terapias para melhorar especificamente a condução 
eléctrica do miocárdio. 
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3. INTRODUCTION 
3.1. Epidemiology of Cardiovascular Diseases 
Cardiovascular diseases (CVDs) consist in a group of conditions that involve the heart 
and/or blood vessels (e.g ischemic heart diseases, cerebrovascular diseases). These diseases 
are the leading cause of mortality worldwide with a current estimation of 17,3 million deaths 
per year (with an expected increase up to 23,6 million deaths by the year 2030), representing 
31% of all global deaths [1, 2] (Figure 1). Although genetic factors can influence the 
occurrence of CVDs, by far, the most relevant risk factors include age, gender, family history, 
physical inactivity, smoking habits, alcohol consumption, obesity, diabetes, hypocholesteremia 
and hypertension [2-4]. Moreover, ischemic heart diseases, i.e. conditions that involve reduced 
blood supply to the myocardium (cardiac muscle), account for 46% and 38% of CVD-related 
deaths for males and females, respectively, and represent, alone, the leading cause of death 
worldwide [2, 5] (Figure 2). Importantly, CVDs are frequently associated to electrical disruption 
and the onset of arrhythmias [6], which can be fatal. In line with this, ventricular arrhythmias 
account for approximately 50% of deaths associated with chronic heart failure [7]. 
 
 
 
 
 
 
Figure 1 – Proportion of causes 
of death worldwide. (NCDs: 
non-communicable diseases; 
e.g. cancer). Source: ref [2]. 
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Figure 2 - Proportion of causes of CVD-related deaths worldwide, in males (left) and females (right). 
Source: ref. [2] 
3.2. Myocardial Infarction: Etiology and Pathophysiology 
As mentioned, ischemic heart diseases are the main cause of CVD-related deaths 
worldwide [2, 5]. One of the most common ischemic heart diseases is the acute myocardial 
infarction (MI). MI can be defined as myocardial cell death due to sustained ischemia at the 
myocardium level [8] and is frequently caused by the rupture of atherosclerotic plaques at the 
coronary arteries (which irrigate and supply oxygen to the myocardial tissue) ultimately leading 
to the rapid formation of a blood clot that results in their occlusion [8, 9]. However, MI can also 
be caused by secondary ischemic imbalances (e.g. coronary artery spasms) and stent-related 
thrombosis [8]. Moreover, MI frequently develops into heart failure [10, 11], which can be 
defined as a pathophysiological state in which the cardiac output is insufficient to assure 
enough blood organ perfusion to meet metabolic demands [12]. 
Owing to the often massive loss of viable myocardium by ischemia-induced 
cardiomyocyte (CM) necrosis, MI frequently results in a pathological remodeling i.e. alterations 
on the size, shape, structure and function of the left ventricle (LV) [13-15]. Initially, CM undergo 
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necrosis since these cells exhibit an high metabolic activity and, therefore, are sensitive to 
ischemia [16]. Then, an acute inflammatory reaction is initiated involving the recruitment of 
neutrophils (that, in mice, starts occurring at around 1-2 days after MI) and macrophages (at 
~4 days, in mice [14]) that phagocyte necrotic CM debris at the infarcted site. The recruitment 
of inflammatory cells is stimulated by the release of, for instance, transforming growth factor 
beta (TGF-β) by necrotic CMs [14, 15]. Of note, neutrophils produce matrix metalloproteinases 
that cleave collagen and other extracellular matrix (ECM) constituents [14, 15, 17]. 
Consequently, these enzymes degrade the collagen-based intercellular struts that, in a healthy 
myocardium, preserve adjacent CMs together and assure proper fiber alignment and 
maintenance of normal CM morphology [17]. Then, due to cell loss and ECM degradation, the 
pressure that the blood on the LV cavity exerts on the infarcted LV wall, causes the CMs to 
slip (CM slippage), resulting in LV wall thinning and LV cavity dilation. At this point, the infarcted 
wall has very low mechanical resistance and the risk of rupture and/or aneurysm formation is 
elevated [14, 15]. Since adult mammalian CMs lack functionally relevant proliferative capacity 
[18], in order to improve mechanical integrity of the LV wall in these phase and equalize the 
forces exerted on LV wall (reducing wall stress), the mammalian heart resorts to a repair 
process, involving collagen deposition. In line with this, TGF-β stimulates fibroblast 
recruitment, massive proliferation and their differentiation to myofibroblasts [14, 15]. These 
cells then produce collagen type I and III resulting in the deposition of a collagen-rich scar 
tissue (fibrosis) at the infarcted zone and, frequently, interstitial fibrosis among viable CMs of 
the periphery [14, 15]. Fibrosis starts approximately at 7-14 days post MI and becomes 
completed at around 21 days, in a murine MI model [14]. Scar tissue, although conferring 
mechanical support to the infarcted wall at some extent, is non-contractile, thick, stiff and 
greatly impairs cardiac contractile function [16]. Moreover, collagen scarring is an electrically 
isolating tissue, which has a detrimental effect on cardiac conduction. Of note, increased wall 
stress and mechanical load as well as fibrosis triggers compensatory processes such as CM 
hypertrophy, where CMs increase their volume and further develop their contractile apparatus.  
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Due to functional impairment provoked by the exacerbated loss of CMs and 
subsequent formation of non-functional fibrotic tissue in a MI scenario and the fact that heart 
transplantation (the only effective long-term therapy for heart failure) has several shortcomings 
(e.g. organ donor shortage, immune rejection [14]) innovative therapeutic strategies have been 
emerging. Most of them focus on the improvement of heart function and cardiac remodeling 
(reviewed on [19, 20]). However, considering that arrhythmias are a main cause of sudden 
death in heart failure scenarios, a comprehensive understanding of the cardiac electrical 
system should not be disregarded and novel therapies to restore cardiac electrical integrity are 
necessary. 
 
Figure 3 – Schematic representation of the several processes occurring during MI-related cardiac 
remodeling. AII – angiotensin II; ACE - angiotensin-converting enzyme; ECM – extracellular matrix; ET-
1 – endothelin; CO – Cardiac Output; MMP – matrix metalloproteinase;; NE – norepinephrine; RAAS - 
renin-angiotensin-aldosterone system; TIMPs – tissue inhibitors of metalloproteinases. Source: ref. [15]. 
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3.3. Cardiac Electrical System: the basics 
A close interaction between specialized excitatory and conductive components and 
the working CMs (contractile component) is essential for the successive and rhythmic 
contractions and relaxations of the myocardium, which promote unidirectional blood flow at an 
adequate pressure [21, 22]. 
The main elements of the excitatory and conductive components are the sinoatrial 
node (SAN), the internodal pathways, the atrioventricular node (AVN), the bundle of His and 
the Purkinje fibers [22, 23] (Figure 4). This system is mainly composed of specialized CMs 
whose cytoarchitecture and electrophysiological properties vary according to their specific 
function and differ from working atrial and ventricular CMs [23-25].  
Specialized CMs of the SAN, regulated by sympathetic and parasympathetic stimuli, 
spontaneously generate AP that directly propagates to: 1) the atrial myocardium leading to its 
contraction; 2) the internodal pathways; and, ultimately, to 3) the AVN. At the latter, the impulse 
propagation suffers an essential delay in order that blood from the atria fills the ventricles 
before ventricular contraction. Finally, the AP is propagated rapidly through the bundle of His 
and Purkinje fibers towards the ventricular working myocardium, which then contracts in 
syncytial manner [22, 26] (Figure 4). 
At the cellular level, cardiac AP represents the variations of the CM membrane 
potential that follow an initial depolarization from a resting potential (-85 mV in working CMs) 
to a threshold potential (-40 mV), in a sequence of events mediated by ion channels. 
Essentially, in working CMs this AP can be divided in five phases (Figure 4): a) phase 0: upon 
stimulation from neighboring cells and depolarization to -40 mV, membrane voltage-gated fast 
Na+ channels (NaV1.5 channels) open which causes a rapid intake of Na+ ions (INa currents) 
triggering a further depolarization to a peak of, approximately, +20 mV [21, 26-29]; b) phase 1: 
NaV1.5 channels close and K+ channels (e.g. KV4.2, KV4.3) open leading to a transient outward 
K+ current (Ito) and, consequently, to a transient repolarization [21, 26, 28-30]; c) phase 2: 
opening of slow L-type calcium inward channels (CaV1.2) concomitant with the current 
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mediated by rapidly (IKr currents) and slowly (IKs currents) activating delayed outward rectifying 
K+ channels (e.g. voltage-activated potassium channels (KV11.1) and voltage-gated potassium 
channels (KV7.1), respectively), maintain the AP in a relatively constant depolarized state 
(plateau) [21, 26, 28, 29, 31]; d) phase 3: CaV1.2 channels close and IKr and IKs cause a rapid 
repolarization to the resting potential [21, 26, 28, 29]; e) phase 4: the membrane potential is 
maintained at a resting level by K+ inward rectifier channels (e.g. KIR2.1) (IK1 currents) [21, 26, 
28, 29]. Although working CMs need to be depolarized by neighboring cells, specialized CMs 
of the SANs and AVNs and Purkinje fibers, the so-called pacemaker cells, are able to 
spontaneously generate AP. This property is closely related to an unstable, and less negative 
resting potential (around -55 mV) comparing to working CMs. Such less negative resting 
potential is mainly due to an increased leakage of Na+ resulting in an inward current of these 
ions (the pacemaker current, If) and that is mediated by the hyperpolarization-activated, cyclic-
nucleotide-gated channels [32]. This If current, and the fact that most fast Na+ channels are 
closed at potentials at -55 mV or higher, result on a slow diastolic depolarization of pacemaker 
cells (phase 4). When membrane potential reaches a threshold level, T-type (e.g. CaV3.1) and 
slow L-type Ca2+ channels open, depolarizing the cell up to +20mV (phase 0) (Figure 4) [22, 
26, 29, 33].  
The cardiac AP triggers the contraction of working CMs, allowing contraction of the 
atria and ventricles, through a process denominated excitation-contraction coupling. 
Depolarization of sarcolemma induces opening of L-type Ca2+ channels and, the subsequent 
increase in intracellular Ca2+ concentration, activates the ryanodine receptors (which are 
intracellular Ca2+ channels) in the sarcoplasmic reticulum’s membrane, leading to release of 
this ion from the sarcoplasmic reticulum to the sarcoplasm, further increasing Ca2+ intracellular 
concentration [21, 34]. These ions bind to subunit C of troponin which causes a conformational 
change freeing the actin’s myosin-binding sites from tropomyosin, leading to sarcomere 
contraction [21, 35]. 
 
7 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - Representation of the anatomy of the cardiac conduction system and the path of the action 
potential propagation throughout the structures (arrows) including the time delay observed at the AV 
junction (purple arrow). The shape of the action on SAN (Upper left) and working myocytes (Lower right) 
are represented along with the respective resting potentials and the different phases of the signal 
(numbers).  
Finally, Ca2+ baseline intracellular levels are restored mainly being pumped back to the 
sarcoplasmic reticulum through the sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) or 
released from the cell via Na+/Ca2+-exchangers [21, 36]. There are evidences that, acting in 
late phase of the diastolic depolarization in pacemaker cells, this Ca2+ cycling also promotes 
spontaneous beating (the “calcium clock”), acting in combination with the membrane potential 
instability and If current [37, 38]. 
Impulse propagation between CMs is dependent on intercellular electrical coupling 
i.e. the ability of one cell to transport ions directly from its sarcoplasm to a neighboring one. 
This coupling is predominantly achieved through gap junctions which consist in two exactly 
aligned hemichannels, one from each coupling cell, composed of six subunits of connexin (Cx) 
proteins [39]. Cx45, Cx40 and Cx43 are the predominant isoforms expressed in CMs [40, 41]. 
Cx43 is the predominant isoform of adult working CMs [42-44] whereas Cx40 is expressed in 
His-Purkinje fibers and atrial working CMs (but not in ventricular working CMs) [43-46], and 
Cx45 expression is predominantly found at the AVN [44, 47, 48]. These three Cx isoforms 
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display different levels of conductance: Cx40 has the highest conductance and Cx45 the 
lowest [49-53]. Interestingly, these characteristics correlate with the velocity of impulse 
propagation characteristic of the different structures i.e. his-Purkinje fibers are fast-conducting 
structures, while the AVN is associated with a time delay in AP propagation, however this effect 
is also potentiated by smaller and less abundant gap junctions [47, 54]. Despite the widely and 
classical perception that impulse propagation between CMs is primarily through gap junctions 
(electrotonic model), there are evidences that intercalated discs may actively influence cell-
cell impulse transmission, involving differential NaV1.5 channel expression and extracellular 
space charge variations (ephaptic model) [reviewed on 55, 56]). 
3.4. Disruption of Electrical Conduction after MI and Heart Failure 
Cardiac electrical disruption often results in arrhythmias, which can comprise, for 
instance: altered heart rates (bradyarrhythmias and tachyarrhythmias corresponding to low 
and high heart rates, respectively); premature beats; atrial flutter; and fibrillations which 
comprises an unorganized AP propagation through the myocardial mass resulting in 
uncoordinated contractions and relaxations between different regions of the myocardium, 
which can be supraventricular (e.g. atrial fibrillation) or ventricular [57, 58]. 
Bradyarrhythmias are mainly caused by either SAN dysfunction (sick sinus syndrome) 
or disruption of the AVN conduction (AVN block or heart block). Considering that MI results in 
the deposition of a fibrotic tissue that it is not electrically conductive on myocardium rather than 
necessarly causing impaired of AP signal generation and/or AP propagation at a more central 
level of the specialized conductive system, this section focuses on tachyarrhythmias and 
fibrillations rather than bradyarrhythmias. 
Tachyarrhythmias and fibrillations are frequently associated with CVDs, especially in 
heart failure scenario. The arrhythmogenic properties underlying heart failure are due to 
different factors, namely: ion channel remodeling; reduced excitability; impaired Ca2+ cycling; 
decreased intercellular electrical coupling; and formation of electrically isolating fibrotic tissue 
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[6, 59]. Concerning ion channel remodeling, evidences show that, upon heart failure, there is 
a reduction on the expression of ion channels related to repolarization currents (e.g. Ito, IKs) 
with concomitant increase in a delayed inward Na+ current. These events result in prolonged 
AP duration, which promotes the occurrence of Ca2+-mediated after-depolarizations. Reduced 
excitability, for instance during acute MI, usually occurs due to different factors such as 
increased K+ extracellular concentration. The main effect of the latter is depolarization of 
cardiomyocytic resting potential, which induces a partial inactivation of the voltage-gated Na+, 
reducing INa current and, consequently, excitability and conduction velocities. Reduced 
conduction velocities promote the onset of reentrant arrhythmias, as discussed below in this 
section. Calcium cycling is also commonly affected during heart failure, for instance, increased 
diastolic intracellular Ca2+ concentration, mainly due to higher leakage from the sarcoplasmic 
reticulum (related to impaired ryanodine receptor function) and/or a decrease reuptake of this 
ions from the sarcoplasmic reticulum (due to SERCA2a defective activity), are observed. This 
increase on the diastolic concentration also triggers after-depolarizations [59-62]. Concerning 
intercellular electrical coupling, Cx43 expression is reduced up to 50% in heart failure [63, 64]. 
Apart from causing conduction deceleration and discontinuity, defective intercellular coupling 
between the CMs also results in an increased subthreshold depolarization, which slowly 
inactivates the voltage-gated Na+ channels, further reducing the INa current, and excitability [6, 
59]. Furthermore, deposition of collagenous scar tissue, which is an electrical insulator, is 
common to a wide number of cardiovascular disorders and is particular evident after MI. 
Collagen deposition results on electrically isolated fibers of viable myocardium, discontinuing 
the conduction path and, globally, reducing the AP propagation velocity and, consequently, 
promoting the onset of reentrant arrhythmias [6, 59].  
The most common phenomenon underlying the maintenance of ventricular and 
supraventricular (e.g. atrial fibrillation) tachyarrhythmia and fibrillations is the “reentry” 
mechanism. This can occur in a region of the myocardium in which AP encounters a path 
divided in two, a fast pathway (normal) and a slow pathway (for instance, a myocardial network 
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containing scar tissue), and which converge again in a downstream position of the path. This 
situation can lead to the creation of successive AP propagation cycles , in which AP propagates 
in circles, around the referred fast and slow pathways, and also backwards, increasing the 
frequency of excitation and, consequently, the heart rate. One pre-requisite for an anatomical 
reentry cycle to be sustained is the wavelength of the signal (defined as the product between 
the conduction velocity and the duration of refractory state) to be shorter than the physical, 
anatomical path in which the cycle occurs [6, 57, 59, 65]. 
The most common therapies that are available nowadays for tachyarrhythmias are: i) 
anti-arrhythmic drugs, which still have low efficacy and can, in specific circumstances, even 
aggravate the disorder [66, 67]; ii) implantable cardioverter defibrillators, which only act upon 
the onset of arrhythmias and have the issues shared with implantable devices [68]; and iii) 
surgeries such as AVN ablation on atrial fibrillation patients, which consists in permanently 
disrupting AVN (protecting the ventricles from the arrhythmic signal originated in the atria) and 
thus requiring the permanent use of an implantable pacemaker [69]. 
3.5. Novel Strategies To Restore Myocardial Electrical Conduction following MI 
Functionally proficient cardiac electrical coupling highly depends on molecular players 
(e.g. ion channels, gap junctions) thus, gene-related therapies along with targeted delivery, 
hold high potential for restoring cardiac electrophysiology. In addition, the potential of cell 
therapies to modulate cardiac electrical integrity has also been under recent scrutiny (Figure 
5).  
Gene therapy approaches for treating or reducing the symptoms of ventricular or 
supraventricular tachyarrhythmias or fibrillations essentially involve: 1) direct repair of 
intercellular conduction – mainly by overexpressing connexins [6, 70-72]; 2) modulation of AP 
characteristics – such as increasing the AP upstroke velocity or altering AP duration or 
refractory period [73-75]; and 3) restoration of calcium cycling – predominantly by upregulating 
SERCA2a [76-78]. 
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In most studies, animal models of MI and atrial fibrillation were used. In general, these 
strategies resulted in a reduced rate of occurrence of ventricular arrhythmias; reduced 
ventricular arrhythmia inducibility, assessed by programmed electrical stimulation of the 
myocardium and electrocardiograms (ECGs); and increased conduction velocities, observed 
through ex vivo optical mapping and in vivo invasive electrograms. Of note, the approach 
concerning the restoration of Ca2+ cycling through SERCA2a overexpression is not only being 
applied in several animal models, but also in humans, particularly in the Calcium-Up-
Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) 
phase 1/2 clinical trial [79-81]. In this trial, recombinant adeno-associated viral vectors 
encoding for the human SERCA2a gene (AAV1/SERCA2a) were injected in patients with 
advanced heart failure which, during a 12-month follow-up, exhibited reduced symptoms and 
improved functional status, biomarker profile and LV function [80]. Additionally, patients 
presented less cardiovascular events and/or deaths following 3 years, when compared to 
placebo groups [81]. Curiously, although overexpression of SERCA2a in ischemia-reperfusion 
MI rat and porcine models decreased the number of life-threatening arrhythmias, that effect 
was not observed or even reversed in permanently occluded rat and porcine models of MI, 
probably to the fact that the Ca2+ cell overload and instability are more significant during 
reperfusion, rather than in a lasting ischemic state [82, 83]. This result underlines that the 
efficiency of a developed therapy may be highly dependent on the targeted condition and 
shows the importance of using different ischemic models for the treatment of a disease, as is 
the case of acute MI. Hence, the etiology of arrhythmias in that particular condition should be 
carefully considered for when developing novel therapeutic solutions. For instance, since AP 
propagation is dependent on the fast inward Na+ currents, one would hypothesize that in heart 
failure scenarios, in which detrimental ionic channel remodeling occur, NaV1.5 channel 
overexpression would have potential in restoring conduction and preventing the occurrence of 
reentrant arrhythmias. However, MI causes a general membrane depolarization, leading to 
NaV1.5 channel inactivation which could hinder the usefulness of its overexpression. In that 
regard, a skeletal Na+ channel isoform (NaV1.4), which inactivates at a less negative voltage, 
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has been tested. This isoform results in a less extensive AP upstroke in vitro in CMs subjected 
to a depolarizing medium and has anti-arrhythmic effects in vivo [73-75]. Connexin-related 
strategies are an interesting example how one should not overlook the potential detrimental 
consequences of anti-arrhythmic strategies on the overall homeostasis of the myocardium, in 
the context of certain disease scenarios. Studies involving connexins overexpression had 
promising results [70, 71], however, it has also been shown that overexpressing Cx32 in a 
canine MI model causes an increase on the infarct size [72] by supporting the spread of 
inflammatory mediators throughout the myocardium [84]. Thus, although connexins could 
restore electrical integrity aspects of the myocardium, it could also negatively interfere with the 
myocardial repair and even have proarrhythmic effects due to increased scarring, reinforcing 
the notion that strategies should be thought in an integrative manner. 
3.5.1. Role of cell therapies on cardiac electrical integrity 
Considering the limitations of gold-standard therapies for CVDs and the often 
deleterious LV tissue remodeling characteristic of myocardial repair, novel strategies focusing 
on improving the latter process have been emerging. Cell therapies are one of the most 
extensively explored approaches, which involve different cell types (e.g. mesenchymal stromal 
cells (MSCs), skeletal myoblasts, embryonic stem cells (ESC)-derived CMs (ESC-CMs), 
cardiac progenitor cells) [reviewed on 20, 85]. In these studies, especially in animal models, 
the main assessed outcomes are LV tissue remodeling, neovascularization, and cardiac 
function. In addition, few studies also evaluate whether the aforementioned therapies have an 
effect on cardiac electrical integrity. In that sense, part of the studies in which this effect is 
assessed or that raise pertinent questions, are herein discussed. 
Studies involving MSCs or bone marrow-derived cells have shown promising results, 
in both animal models and clinical trials, such as improved LV function, neovascularization, 
and reduced infarct size [86-91]. Nevertheless, these cells raised controversy concerning their 
influence on cardiac electrical integrity and arrhythmogenicity [92-102]. The authors that show 
evidence that MSCs or bone marrow-derived cells have a pro-arrhythmic potential in vivo [92, 
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93, 103] hypothesize that such effect could be a consequence of the electrical unexcitability of 
these cells, paracrine factors, or the accumulation of inflammatory mediators. Although MSCs 
are electrically unexcitable cells, in vitro studies showed that these cells are capable of 
repairing conduction block, in neonatal CMs cultures, through connexin-mediated coupling 
[104, 105]. Nevertheless, others showed that this heterocellular electrical coupling might cause 
reduced AP propagation velocities and gradients of duration of repolarization which could 
promote the occurrence of reentry circuits and, consequently, arrhythmias [99, 100]. This 
mechanism is similar to the effect of cardiac fibroblasts on cardiac conduction in a context of 
fibrosis, as these cells undergo direct electrical coupling with CMs via gap junctions [106], 
bridging distant unconnected CMs [107]. It is not yet understood whether this “intercellular 
bridges” are arrhythmogenic substrates or if the electrical bridging has also some beneficial 
effects by reducing conduction block through scar tissue. Furthermore, MSC-released 
paracrine factors can also promote disruption of the myocardial electrical integrity not only by 
altering AP characteristics, ion channel expression and increase re-entry inducibility of CMs 
(assessed by in vitro transwell experiments) [100]; but also by promoting cardiac nerve 
sprouting and sympathetic hyperinnervation [93, 103]. Oppositely, others studies point that 
MSCs can reduce the electrical disruption in a MI scenario or even exert an anti-arrhythmic 
effect [97, 98, 101]. Overall, MSCs were shown to decrease ventricular arrhythmia inducibility, 
reduce the disruption of gap junction organization in CMs of the infarct border zone and 
ameliorate the electrical activity. Although mechanistic insights are lacking, the authors 
speculated that gap junction-mediated coupling between MSCs and CMs support AP 
propagation into the infarcted region, reducing the length of the anatomical conduction path 
and reducing the incidence of reentry arrhythmias. Additionally, it was suggested that the lack 
of electrical excitability in combination with the intercellular coupling could not have a 
significant pro-arrhythmic effect because the number of surviving MSCs in the myocardium 
decreases in few days, being the proportion MSCs:CMs much lower than in in vitro 
experiments where arrhythmogenicity was shown. Furthermore, the beneficial effect of MSCs 
on cardiac conduction can also be associated with the decrease in infarct size and increase in 
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the number of surviving CMs in the periphery of the ischemic region. MSCs were shown to 
upregulate Cx43 in HL-1 (CMs cell line) in vitro [96] and improve AVN conduction on AVN-
blocked rats [108] through paracrine mechanisms. Thus, although MSCs are electrically 
unexcitable and incapable of electromechanical coupling with the host myocardium, evidences 
point to beneficial effects in cardiac function in the absence of evident side effects. In fact, 
clinical studies show no conspicuous anti-arrhythmic effect by these cells [94, 95, 109].  
Skeletal myoblasts were one the first the cell types to be applied in animal and clinical 
studies concerning cell therapy on CVDs. This interest mainly stemmed from their capacity to 
proliferate, increased resistance to ischemia; and electrical excitability and the possibility of 
being isolated in an autologous fashion [110, 111]. However, being skeletal muscle cells, these 
cells lack expression of connexins upon the formation of myotubes, exhibiting minimal 
intercellular coupling. This characteristic precludes efficient integration of skeletal myoblasts 
with the myocardium and thus leading to an increased frequency of arrhythmic events, despite 
reported positive effects regarding other aspects [101, 112-114]. Thus, without intercellular 
coupling, these cells form clusters electrically isolated from the myocardium, blocking AP 
propagation in that region, rendering the electrical activity of these cells almost irrelevant. To 
surpass this limitation, some authors overexpressed Cx43 on cultured skeletal myoblasts, 
improving intercellular electrical coupling with CMs [115-117], which stimulated a series of in 
vivo testing [118-122]. Myocardial delivery of these cells in a cryoinjury MI murine model 
improved electrical coupling between skeletal myoblasts and host CMs, being the incidence of 
sustained arrhythmias and the ventricular arrhythmia inducibility decreased when compared 
to regular skeletal myoblast injection [119]. Conversely, although an amelioration of electrical 
coupling and improved electrical activity was observed, other studies involving rat [122] and 
rabbit [120] MI models reported that this coupling was insufficient to prevent arrhythmic events 
and that LV functional improvement was modest. This may relate to distinct AP characteristics 
of skeletal myoblasts which, in a cardiac environment, may also undergo downregulation of 
voltage-gated sodium, potassium and calcium channels [123], affecting their excitability and 
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function. Furthermore, as the clinical relevance of skeletal myoblast relies on Cx43 
overexpression, alternative non-viral methods of gene expression should be further explored 
[121]. One concludes that for cells that survive and proliferate after transplantation, intercellular 
coupling and electrical and mechanical properties that closely mimic native CMs are 
mandatory to promote proper electromechanical function. 
Pluripotent stem cells, which include ESCs and induced pluripotent stem cells 
(iPSCs), are a promising alternative due to their in vitro high proliferative capacity, while in an 
undifferentiated state, and their capacity to differentiate selectively into a great variety of cell 
types. These features allow generation of a great number of CMs which are immature in 
phenotypic and functional features. ESC-derived CMs (ESC-CMs) display immature contractile 
machinery and are capable of spontaneous AP generation. This inherent automaticity 
increases the possibility of induced arrhythmias when ESC-CMs are delivered to the 
myocardium. Despite that transplantation of pluripotent stem cells-derived CMs promote 
successful engraftment and functional improvement [124-128], few studies have thoroughly 
evaluated their electrically integration and/or pro-arrhythmic properties [124, 125, 128]. Shiba 
et al showed, in a guinea pig MI model, that hESC-derived CMs formed cell grafts with calcium 
transients and completely coordinated with ambulatory ECG signals, with evidences of an anti-
arrhythmic effect [124, 128]. The same group applied a similar strategy in a non-human primate 
model of MI showing functional improvement, remuscularization and hESC-CM calcium 
transients completely coordinated with ambulatory ECG signals. Despite these encouraging 
results, all transplanted animals suffered premature ventricular contractions and ventricular 
tachycardias [125]. These opposing results could be explained by the disparity in the heart rate 
of guinea pigs and macaques. High heart rates, typical of small animal models, could mask 
the ESC-derived CM automaticity by surpassing their AP generation frequency. In contrast, in 
both large animal models and humans, the automaticity of these cells can be revealed due to 
slower basal heart rates [125]. Thus, although these cells show a phenotype which closely 
mimics CMs, their immature state can hinder its clinical applicability. Additionally, note that 
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pluripotent stem cells have other hurdles to surpass such as immunogenicity (especially 
regarding ESCs), tumorigenesis by teratoma formation or use of viral vectors (mainly in 
iPSCs), low cell survival and ethical concerns. 
Figure 5 - Scheme representing the discussed gene and cell delivery strategies for altering cardiac 
conduction, along with the delivery sites. A diseased heart with reduced electrical integrity is 
represented. Icons positioned on the gray region are indicative of studies involving MI animal models. 
The cell sources and gene therapies strategies are represented on the side columns 
In conclusion, an ideal cell capable of adequate cardiac electrical integrity, while 
improving cardiac function and tissue remodeling, is yet to be described. Regardless, one must 
reflect on novel therapies on different perspectives: 1) does a certain cell allow sufficient 
improvement in cardiac function and tissue remodeling that compensates for their pro-
arrhythmic potential upon transplantation?; 2) should we focus on cellular genetic manipulation 
to approximate their function and phenotype to native CMs?; 3) can different aspects be 
improved using, for instance, tissue engineering which involves combinatorial and integrative 
approaches?  
3.5.2. Potential of Electrical Cues to Improve Cardiac Tissue Engineering Strategies 
Cardiac tissue engineering strategically combines cells, scaffolds and signaling 
factors to restore cardiac function and/or improve cardiac repair, which can be achieved 
through different approaches, such as: 1) improving therapies based on cell injection by 
providing a vehicles to cells and 2) allowing the formation of cardiac tissue constructs in vitro 
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for subsequent implantation (reviewed elsewhere [19, 20, 129]). Although cardiac tissue 
engineering resulted in promising results, particular in cell survival and engraftment in vivo, 
some limitations still remain. For instance, cardiac tissue constructs, despite exhibiting 
synchronous contractions, spontaneous beating can be observed (mainly with pluripotent stem 
cells) which, as was already discussed can have pro-arrhythmic effects. In order to solve this 
issue, culture conditions have been successively improved by providing biochemical, 
mechanical and electrical cues that closely mimic the native myocardial microenvironment. 
The role of external electrical stimulation has been tested in vitro on cultured cardiac 
cells [130-133]. For instance, Radisic et al. conducted a pioneer work showing that, upon 8 
days of in vitro electrical stimulation, cultured neonatal CMs exhibited increased alignment, 
intercellular coupling, ultrastructural organization and amplitude of synchronous contractions, 
concomitant with improved contractile and electrophysiological proficiency [130]. 
Scaffolds or constructs containing conductive components have been explored to 
originate constructs that mimic the myocardial environment and support functional cardiac cells 
and even their electromechanical integration following transplantation and/or that promote 
electrical integrity of the heart by acting directly on native CMs. The most explored materials 
are: i) gold-based materials, such as gold nanowires (AuNWs) and gold nanoparticles which 
exhibit great biocompatibility, low toxicity and, importantly, high electrical conductivity [134]; ii) 
carbon-based materials, mainly carbon nanotubes (CNTs) due to their high surface area, high 
chemical stability, high mechanical strength and conductivity; iii) intrinsically electroconductive 
polymers; and, more recently, iv) silicon-based approaches. Table 1 summarizes 
representative studies, some of which will be discussed. 
3.5.2.1. Gold-based materials 
In a pioneer study, Dvir et al. integrated AuNWs in the pore walls of macroporous 
alginate scaffolds. Neonatal CMs were cultured on AuNWs scaffolds during 3 days without 
electrical stimulation followed by 5 days of electrical stimulation. While alginate-only scaffolds 
resulted in the formation of small cell aggregates within the pores, Au-NW scaffolds showed 
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thick and aligned cardiac cell constructs. Furthermore, CMs in these scaffolds exhibited Ca2+ 
transients, synchronous contraction and higher amounts of α-sarcomeric actinin and Cx43 
[135]. 
Aiming to mimic the native cardiac ECM fibrous organization, gold nanoparticles 
deposited on fibrous decellularized pig omental matrices promoted Cx43 rearrangement 
between adjacent neonatal CMs organized in elongated, aligned and striated cell constructs 
with stronger contraction forces [136].  
To assure proper alignment and electrical coupling a cardiac patch should also be 
mechanically compatible with the myocardial tissue. Myocardial stiffness in humans is 
approximately 10 kPa and 500 kPa at the beginning and end of diastole, respectively [137]. Of 
note, the majority of studies with gold-based materials summarized in Table 1 report a 
scaffold’s stiffness out of this range (Table 1). Recently, this issue has been addressed through 
incorporation of AuNWs into biodegradable polyurethane porous scaffolds with an elasticity of 
200 to 240 kPa [138]. Electrical stimulation improved H9C2 rat CMs spreading and alignment 
on the conductive scaffolds however, Cx43 expression was unaffected [139]. 
3.5.2.2. Carbon-based materials 
Initial studies showed that neonatal CMs cultured on the top of CNTs on glass 
substrates presented higher metabolic activity, proliferation rates and displayed larger domains 
of syncytial beating. Importantly, whole cell patch clamp recording showed that CMs cultured 
on CNTs for 3 days exhibited more negative membrane resting potential than controls, 
evidencing increased CM maturation [140]. The improved maturation of CMs on CNTs was 
further related with more abundant Cx43 gap junctions and alterations on gene expression 
[141]. 
These 2D approaches advanced to the use of carbon-based 3D ECM-like scaffolds 
such as scaffold comprising poly(glycerol sebacate):gelatin aligned electrospun nanofiber 
embedded with CNTs. Neonatal CMs cultured on CNT-containing scaffolds days had higher 
viability, metabolic activity, increased Cx43 levels, became more aligned and displayed higher 
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beating rates and lower excitation threshold than CNT-free counterparts [142]. An independent 
study showed that CMs cultured on CNT scaffolds augmented conduction velocity, reduced 
AP duration and displayed preferential localization of Cx43 at cell–cell junctions. Of note, 
potential cytotoxic effects of CNTs were demonstrated at high concentrations (175 ppm) [143]. 
In 2014, CNT-based composite cardiac patch were for the first time tested in vivo. CNT-gelatin 
scaffolds seeded with neonatal CMs were implanted on the lesion site of rats 14 days after MI. 
Following 4 weeks of implantation, the boundary between the scaffold and scar tissue was 
unclear and CNT-seeded CMs presented upregulated levels of Cx43, NaV1.5 and N-cadherin 
(typical of intercalated discs). Interestingly, a portion of CNT-seeded CMs migrated to the scar 
tissue, along with CNTs. The scaffold also contained host-derived cells such as CMs, smooth 
muscle cells, and CD68+ macrophages, showing evidences that the scaffold integrated with 
the host cardiac tissue. Heart function assessment showed that ejection fraction and fractional 
shortening were significantly improved [144]. Despite the aforementioned beneficial effect of 
CMs in CNTs, electromechanical coupling with native counterparts and electrophysiological 
influence is yet to be demonstrated. 
Although the majority of the described studies show improved intercellular electrical 
coupling induced by carbon-based materials, the molecular mechanisms that trigger these 
effects are still not well understood. A recent report further demonstrated that CNT-collagen 
seeded CMs induced intercalated disc gap junctions assembly via β1-integrin/FAK/ERK/MEF-
2c and GATA4 signaling pathway [145]. Of note, it remained unclear if CNT-collagen observed 
effects could be attributed to mechanical and/or to electrical cues. 
3.5.2.3. Conductive polymers-based materials 
The two main studied polymers are polyaniline (PANI) and polypyrrole (PPy). Some 
authors explored the capability of PANI-based materials to promote functional proficiency and 
electrical coupling of CMs [146, 147]. Baheiraei et al. explored the properties of porous 
scaffolds composed of polycaprolactone (PCL) and a biodegradable polyurethane polymer 
containing aniline pentamers. This strategy aimed to harness the electroconductive properties 
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of the aniline pentamers while trying to surpass the low biodegradability and poor mechanical 
properties of PANI. Conductive scaffolds promoted neonatal CMs adhesion, growth and higher 
expression of genes involved in contraction and cytoskeleton alignment when compared with 
the control groups. Nevertheless, Cx43 expression levels were not significantly altered [147]. 
Regarding PPy-based materials, CMs were cultured on electrospun nanofibers 
consisting in blend of doped PPy, polycaprolactone and gelatin onto glass coverslips. Overall, 
increasing the concentration of PPy (0-30%) increased tensile modulus: 15% PPy presented 
better conductivity, mechanical properties and biodegradability with seeded CMs displaying 
enhanced performance considering cell attachment, proliferation, interaction, and expression 
of cardiac-specific proteins [148]. More recently, Spearman et al. produced films comprising 
interpenetrating networks of PPy and polycaprolactone. HL-1 atrial myocytes seeded on these 
films remained viable, became more elongated, presented higher levels of Cx43 and increased 
calcium transient propagation velocity and spontaneous electrical activity frequency values 
[149]. 
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Table 1 – Experimental results demonstrating the potential of conductive materials on cardiac tissue engineering. 
Material Refs. Scaffold 
Elastic Modulus (kPa)/ 
Conductivity (S/m) 
Cell Source Main Results 
Gold [135] AuNW-incorporated alginate 
scaffolds 
~3.5/n.a. Neonatal CMs Thick and aligned cell constructs; ↑ α-SA and Cx43; synchronous 
contractions 
 [154] AuNP-deposited PCL fibers ~60x103/n.a. Neonatal CMs Elongated, aligned and striated cell constructs; ↑ contraction rate and 
force 
 [139] AuNP-incorporated 
biodegradable PU scaffolds 
~200-240/n.a. H9C2 rat CMs Improved cell spreading and alignment; ↑ Nkx2.5, ANF, NPPB 
expression 
 [155] AuNP-deposited PCL/gelatin 
scaffolds 
n.a./n.a. Neonatal CMs CMs with elongated shape, conspicuous striation and higher aspect 
ratio; ↑ contraction amplitudes and rates 
 [136] AuNP-deposited decellularized 
pig omental matrices 
~12.5x103/n.a. Neonatal CMs Elongated, aligned and striated cell constructs; Cx43 staining localized 
between adjacent CMs; ↑ contraction amplitude, calcium transient 
propagation velocity; ↓ excitation threshold 
 [156] AuNP-deposited thiol-
HEMA/HEMA scaffolds 
~600-1600/~11-15 Neonatal CMs CMs presented as clusters or single cells; 2-fold ↑ Cx43 protein levels 
 [157] AuNW-incorporated GelMA 
hydrogels 
~1.3/ n.a. Neonatal CMs ↑ cell retention and viability; highly organized sarcomeric structures; ↑ 
beating frequency; more synchronous, stable, and robust beating 
behavior; synchronized calcium transients; ↓ excitation threshold 
Carbon [142] MWCNT-embedded PG 
nanofibers 
~373.5/n.a. Neonatal CMs ↑ CM alignment, metabolic activity and viability; ↑ Cx43 staining 
 [140, 141] MWCNT solution coating a 
glass substrate 
n.a./n.a. Neonatal CMs ↑ metabolic activity; more negative membrane resting potential; ↑ 
αMHC, SERCA2a, Cx43; ↓ ANF 
 [158] Chitosan:CNTs composite 
scaffolds 
~28.1/~0.25 (hydrated) Neonatal CMs ↑ CM alignment and metabolic activity; ↑ TnI, SERCA2a, GATA4, 
αMHC, Cx43, βMHC and ANF expression 
 [143] SWCNT-incorporated gelatin-
chitosan hydrogels 
~19.3 (175 ppm)/n.a. Neonatal CMs Concentration-dependent cytotoxicity; more developed sarcomeres; ↑ 
α-SA protein levels; intercellular Cx43 stainings; ↑ beating rates and 
conduction velocity; ↓ AP duration 
 [159] CNT-embedded GelMA 
hydrogels 
~20-54/n.a. Neonatal CMs Aligned, interconnected CMs; developed sarcomeres;  attenuation of 
heptanol-induced intercellular coupling inhibition 
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 [160, 161] PLGA:CNFs composite 
substrates 
n.a./~5x10-4 – 7x10-3 Human CMs, rat 
ECs & NIH/3T3 
rat fibroblasts 
↑ CM density; ↓ ECs and fibroblast growth 
 [145] SWCNT/collagen solution 
coating a glass substrate 
n.a./ ~1.90x10-8 – 
1.77x10-3 
Neonatal CMs Marked striation and organized sarcomeres; functional beating 
syncytium; ↑TnI, Cx43, N-cadherin, plakophilin2 and plakoglobin 
expression; well-developed intercalated disc junctions; ↑ β1-integrin, 
FAK, p-ERK, MEF-2c and GATA4 
 [144] SWCNT-incorporated gelatin 
hydrogels 
n.a. (shear modulus:~ 
20-400 Pa)/ ~5x10-5 
Neonatal CMs In vitro:  aligned cell constructs; organized sarcomeres; ↑ α-SA and 
Cx43 levels; spontaneous electrical activity; 
In vivo (MI rats): ↑ Cx43, NaV1.5 and N-cadherin protein levels; unclear 
scaffold/scar boundary; presence of host-derived smooth-muscle cells 
and CD68+ macrophages; ↑ ejection fraction and  fractional shortening 
Conductive 
polymers 
[147] PCL/PU blend scaffolds 
containing aniline pentamers 
~1.3x103/~10-4-104 Neonatal CMs ↑ TnT, Cx43, actinin-α-4 
 [146] Nanofibrous 2D meshes of HCl-
doped PANI/PLGA blend 
~91.7x103/~0.31 Neonatal CMs Isolated cell clusters; spontaneous beating activity; ↑ TnI, Cx43 
expression;  intercellular Cx43 localization 
 [148] PPy/PCL/gelatin blend 
nanofibers on glass substrate 
~16.8x103/~1.3x10-3 Rabbit CMs ↑ α-SA, TnT and Cx43; increasing PPy proportion disrupted 
mechanical properties and slowed CM growth 
 [151] Injectable PPy-grafted chitosan 
hydrogel 
~2/~0.02 Neonatal CMs In vitro: ↑ Ca2+ transients velocity; 
In vivo (MI rats): QRS interval duration similar to healthy; ↑ transverse 
and border zone/scar region conduction velocities; ↑ ejection fraction, 
dP/dt max and min, preload recruitable stroke work; 
 [149] Films of interpenetrating PPy 
and PCL networks 
~9.3x105/~0.10 HL-1 murine 
atrial myocytes 
↑ proportion of cells with peripheral Cx43 expression;↑ Ca2+ transients 
velocity and spontaneous electrical activity frequency 
Silicon [152, 153] SiNW-incorporated cardiac cell 
spheroids 
n.a./150-500 Neonatal CMs or 
hiPSC-derived 
CMs 
Improved intercellular coupling (e.g. ↑ Cx43 and N-cadherin); improved 
contractile machinery development; ↑ β-MHC/α-MHC ratio; ↓ 
spontaneous beating frequency 
n.a. – non-available; αMHC, alpha myosin heavy chain; α-SA, alpha-sarcomeric actinin; βMHC, beta myosin heavy chain; ANF, atrial natriuretic factor; AuNP, gold nanoparticle; 
AuNW, gold nanowire; CM, cardiomyocyte; CNT, carbon nanotube; CNF, carbon nanofibers; Cx43, connexin-43; EC, endothelial cell; ERK, extracellular-signal-regulated kinase; 
ESC, embryonic stem cell; FAK, focal adhesion kinase; GelMA, gelatin methacrylate; HEMA, hydroxyethylmethacrylate; hiPSCs, human induced pluripotent stem cells; MEF-2c, 
myocyte-specific enhancer factor 2C; MHC, myosin heavy chain; MI, myocardial infarction; MWCNT, multi-walled carbon nanotube; NPPB, natriuretic peptide precursor B; PANI, 
polyaniline; PCL, polycaprolactone; PECAM1, platelet endothelial cell adhesion molecule 1; PLGA, polylactic-co-glycolic acid; PPy, polypyrrole; PU, polyurethane;  SERCA2a, 
sarcoplasmic reticulum Ca2+ ATPase 2a; SiNW, silicon nanowire; SWCNT, single-walled carbon nanotube; TnI, troponin I; TnT, troponin T 
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Similarly to the other conductive materials, in vivo studies involving electroconductive 
polymers are scarce, being the few existent dedicated to cell-free injectable PPy-based 
hydrogels rather than tissue engineered cardiac patches [150, 151]. Notwithstanding, a recent 
study addressed the effect of an injectable hydrogel composed of PPy-grafted chitosan, on 
cardiac function and AP propagation in a rat MI model. The hydrogel was administered to the 
infarcted LV 1 week after MI. Eight weeks after injection the treated group showed improved 
LV function and QRS interval duration of PPy/chitosan-injected heart was similar to that of 
healthy animals [151]. 
3.5.2.4. Silicon-based approaches 
Recently, when incorporated in spheroids comprising of neonatal rat CMs or human 
iPScs-derived CMs, silicon nanowires were shown to enhance contractility and 
synchronization and increase expression of α-sarcomeric actinin and Cx43 [152, 153]. 
Furthermore, silicon nanowires and electrical stimulation had a synergistic effect on hiPSC-
derived CMs spheroids which presented more developed sarcomeric apparatus, improved 
intercellular coupling, higher degree of maturation and reduced spontaneous beating 
frequency [152]. 
Overall, conductive scaffolds showed promising results as potentiate the formation of 
aligned, striated and synchronously contracting CMs, exhibiting increased calcium transients 
and AP propagation velocities and higher contractility forces (Table 1). Additionally, 
upregulation of CM maturation-associated genes and/or functional proficiency was also 
observed (Table 1). Constructs were often beating spontaneously, underlining that electrical 
cues were not sufficient to obtain full maturation. Notwithstanding, it is conceivable that full 
maturation could only be obtained upon implantation. In line with this, some authors appear to 
consider an increase in beating frequency as a positive outcome however it could be 
associated with increased automaticity and, thus, a pro-arrhythmic tendency upon 
implantation. It should also be noted the lack of in vivo studies involving conductive materials. 
In order to ascertain whether these materials have clinical applicability in a near-future, in vivo 
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studies with thorough electrophysiological assessments in larger animal models (e.g. pig) are 
warranted. Apart from their potential for altering in vivo electrical integrity, other essential 
issues such as biocompatibility, concentration-dependent toxicity (especially for CNTs) and 
poor mechanical properties (mainly for electroconductive polymers) should also be evaluated.  
3.6. Final Remarks 
The reported progresses show the relevance of considering cardiac electrical integrity 
as a central aim of innovative therapies. Promising results stemmed from both gene and cell 
therapies that aimed to restore a defective electrical conduction system. In a CVDs involving 
extensive loss of CMs, as is the case of MI, an efficient therapy must rely not only in CMs 
replacement but also in restoring myocardial electrical integrity and/or arrhythmogenicity. 
Hence, conductive biomaterials coupled or not with external electrical stimulation may 
enhanced the outcome of conventional tissue engineering strategies by promoting cell-
biomaterial-myocardium electromechanical integration. Future studies exploring combinatory 
therapies to promote electrical integrity and CMs replacement in clinically relevant in vivo 
models and further dissection of the underlying mechanisms, are warranted (Figure 6). 
 
Figure 6 - Summary of 
discussed approaches with 
great potential to restore 
electrical integrity, and that 
are amenable to be 
combined as a 
electromechanical integrated 
biomaterial-based patch. 
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4. PRELIMINARY RESULTS 
Apart from the mentioned studies addressing potential of electrical cues in the form 
of conductive materials, the role of external electrical stimulation alone has also been tested 
in vitro on cultured cardiac cells, with promising results [130-133]. For instance, Radisic et al. 
conducted a pioneer work in which it has been shown that, upon 8 days of in vitro electrical 
stimulation, cultured neonatal CMs exhibited increased alignment, intercellular coupling, 
ultrastructural organization and amplitude of synchronous contractions, concomitant with an 
improvement of contractile and electrophysiological proficiency [130]. In that sense, in the 
context of a cardiac tissue engineering applications, it would be of interest to further evaluate 
the effect of adequate in vivo electrical stimulation. Currently, that would imply the use of 
external electrical stimulation, which is impractical. Piezoelectric materials could comprise a 
future solution for this issue, as discussed below.  
A given material is considered piezoelectric when it exhibits an electric polarization 
(and a resultant electrical activity) upon mechanical stress (direct effect) or vice-versa 
(converse effect). Furthermore, in order to exhibit piezoelectricity, the molecular structure of a 
given material must present a certain anisotropy [162].  
Although most common applications for piezoelectric materials are related to 
electronics and sensors, biomedical applications have been encouraged for these materials 
due to their inherent potential to provide electrical stimuli in the absence of an external 
electrical source by, for instance, harnessing body movements, added to the fact that some 
biological tissues naturally exhibit piezoelectric properties (e.g. bone, tendons) [163-165]. 
Particularly for tissue engineering approaches, most studies have been focusing on bone and 
neural tissue engineering, which are out of the scope of the herein work and are reviewed 
elsewhere [166, 167]. Nevertheless, it is worth mentioning that the most commonly used 
piezoelectric materials on these studies are the lead zirconate titanate (a piezoceramic) and 
polyvinylidene fluoride (PVDF) and its co-polymers (a piezoelectric polymer) [166]. 
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Since the heart exhibits robust cyclic movements, the implantation of these materials 
on an injured myocardium holds great potential as could be possible to obtain a sustainable 
electrical activity, induced by native mechanical stimuli, with a consequent improvement of 
electromechanical integration and cardiac function. Nevertheless, studies applying 
piezoelectric materials on cardiac tissue engineering are scarce [168]. In fact, to our 
knowledge, up to this point, only one in vitro study has been published in that line. CMs derived 
from mouse embryonic stem cells were cultured on a scaffold composed of aligned 
poly(vinylidene fluoride–trifluoroethylene) (PVDF-TrFE) co-polymer piezoelectric fibers [168]. 
The formed cell constructs became striated and were aligned with the fibers, while presenting 
spontaneous synchronous contractions throughout the scaffold. Furthermore, cardiac troponin 
and alpha myosin heavy chain protein levels were increased when compared with 2D culture 
dish controls. However, the former had Cx43 significantly decreased protein levels, suggesting 
a reduction in intercellular coupling. Regarding electrophysiological parameters, although the 
cells cultured on the piezoelectric scaffolds exhibited increased calcium transient amplitude, 
calcium fractional release and responsiveness to adrenergic stimulation, they also presented 
a longer calcium transient duration, which can be associated with an impaired ability of calcium 
reuptake [168]. 
Moreover, under the scope of a research line in the laboratory of Dr. Lino Ferreira 
(Biocant/CNC), neonatal rat CMs were cultured on materials comprising PCL thin-films, over 
which PVDF-TrFE piezoelectric fibers were electrospun. Briefly, results showed that these 
piezoelectric materials sustained CM viability, promoted their alignment and contractility in vitro 
for at least 12 days (Figure 7), induced an upregulation of relevant ionic channel subunits, such 
as alpha 1C (Cav1.2), and 1D (Cav1.3) subunits of L-type Ca2+ channels, Nav1.5, Kv7.1 and 
Kv11.1 (hERG) (Figure 8), and increased expression of functional Cx43 while improving 
calcium handling (Figure 9) (unpublished data). 
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Figure 7 - Piezoeletric fibers-containing materials allow CM viability, alignment and increase beating 
frequency. (A) – viability as assessed by MTT assay; (B) – Cardiomyocyte alignment index; (C) – CM 
beating frequency when cultured on films PS – Polysterene; MNF – magnetic nanofilm.. 
Figure 8 - Cellular expression of ion channels as assessed by quantitative RT PCR. . Cells cultured 
on PS or MNF+PIEZO at day 1 and day 12 were used for these analyses. Target genes include: voltage 
gated Ca2+ channel subunits Cav1.1 (CACNA1S), Cav1.2 (CACNA1C), Cav1.3 (CACNA1D), voltage 
gated Na+ channel subunits Nav1.1 (SCN1A), Nav1.5 (SCN5A), Nax (SCN7A), voltage gated K+ 
channel subunits Kv7.1 (KCNQ1), Kv11.1 (KCNH2). Target genes were normalized against TBP gene 
expression. Results are Average ± SEM, n=4. *Denotes statistical significance: *P<0.05, **P<0.01, 
***P<0.001. PS – Polysterene; MNF – magnetic nanofilm. 
A B C 
28 
  
Figure 9 - Piezoelectric fiber-based materials increase the proportion of function Cx43 and improves 
calcium handling. (A) Ratio of phosphorylated versus total Cx43, at day 1 and 12 of culture (n = 3, 3 
replicas at minimum). (B) Normalized fluorescence signal in cardiac cells cultured in PS and 
MNF+PIEZO, in the absence and presence of epinephrine. Fluorescence intensity values in each 
experiment were normalized by the minimum background intensity registered during that recording. 
The promising results obtained in the aforementioned work motivated the assessment 
of the therapeutic effect of piezoelectric-containing thin film materials on an animal model of 
heart failure. In line with this, the work of the herein Master thesis emerged from this motivation 
and, thus PCL films deposited with piezoelectric PVDF-trFE fibers were applied in a murine 
model of MI. 
  
A B 
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5. AIMS 
Although a tissue engineering approach with piezoelectric materials is yet to be tested 
in vivo, these materials have been already tested in vivo in the heart in the context of other 
applications [169-171]. Recently, Dagdeviren et al. produced thin-film flexible lead zirconate 
titanate-based mechanical energy harvester circuit incorporated in a polyimide layer and 
connected to both a rectifier and a 3.2 V rechargeable battery. Upon suturing of these films, in 
vivo, on the epicardium of healthy swine, ovine and bovine hearts, the authors observed that, 
although the efficiency of the mechanical to electrical energy conversion was around 2%, the 
energy induced by the heart movements on the piezoelectric film was sufficient to recharge 
the battery, upon both open and closed chest assessments. Furthermore, it was also verified 
that by stacking multiple layers of these films would allow this system to support the power 
consumption of an electronic pacemaker device [170]. Thus, this proof-of-concept study shows 
that it is possible to obtain significant amounts of energy by harnessing heart movements 
through piezoelectric materials, which further underlines the need to explore these systems on 
cardiac tissue engineering approaches. These results, in combination with the ones obtained 
in the preliminary work outlined above strongly encouraged the testing of the therapeutic 
potential of the piezoelectric materials on an in vivo MI model. 
Thus, the main aim of work of the herein Master thesis was to evaluate the 
therapeutic potential of piezoelectric fibers-coated thin films for the treatment of MI. For 
that purpose, PCL thin films containing deposited PVDF-TrFE piezoelectric fibers were 
implanted (as patches) in the epicardium of in adult murine model of MI, in order to assess if 
said materials induced some kind of response (beneficial or detrimental). Depending on the 
observed response, one can reflect on the potential of using these materials as, for instance, 
tissue engineering scaffolds or in combination with other therapies. PCL-thin films containing 
deposited PCL fibers were used as control. 
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Hence, the detailed specific aims of the herein MSc thesis were: 
- To optimize the method of surgical patch fixation to the heart of on adult C57BL/6 mice 
immediately after MI; 
- To characterize the functional impact of the Piezo patch on cardiac function 30 days 
following MI by echocardiography and electrocardiography 
- Determine the impact of Piezo patch on the extent of cardiac remodeling and infarct 
size 30 days after MI 
- Evaluate the local response to the patch by histological analysis and detection of 
relevant proteins (CD45, alpha-smooth muscle actin (α-SMA) and Cx43) by 
immunofluorescence. 
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6. MATERIALS AND METHODS 
6.1. Animals, Ethics And Regulation 
Adult female C57BL/6 mice aged 8 to 10 weeks (Charles River) were used in this 
work. All the animal experimental procedures were approved by the i3S (Instituto de 
Investigação e Inovação em Saúde) Animal Ethics Committee, and by the Direção-Geral de 
Alimentação e Veterinária (DGAV). These procedures are in conformity with the European 
Directive 2010/63/EU [172]. Humane endpoints were considered according to OECD 
Guidance Document on the Recognition, Assessment, and Use of Clinical Signs as Humane 
End points for Experimental Animals Used in Safety Evaluation (2000) [173]. 
6.2. Patches 
Although the production of the used patches was not performed in the herein work, 
the patch production methodology and their characterization are briefly described, for 
contextualization purposes. 
Two types of patches were used: 1) the control patches, 400 nm-thick 20 mg/mL 
polycaprolactone (PCL) films coated with aligned PCL fibers, and that will be referred as “PCL 
patches” from this point on; and 2) the test patches, 400 nm-thick 20 mg/mL PCL films coated 
with aligned fibers composed of a piezoelectric copolymer, the poly(vinylidene fluoride–
trifluoroethylene) (PVDF-TrFE), that will be herein referred as “Piezo patches”. 
PCL films were obtained by spin-coating in combination with a sacrificial layer 
approach. The sacrificial layer was obtained by spin-coating a water-soluble polymer, the 
polyvinyl alcohol (PVA) (1% w/v, in water; 1 ml; Mw = 25.000, 88% hydrolysed; Polysciences, 
Inc, over a silicon wafer (400 μm thick, 2 x 2.5 cm; Primewafers) at 4000 rpm for 20 seconds 
(Spincoat G3P- 8, Pi-Kem). Furthermore, a PCL solution (20 mg/mL in chloroform; Mw=80000, 
Aldrich) was spin-coated, with the same parameters, over the sacrificial layer. This sacrificial 
layer strategy allows the PCL films to detach from the silicon wafers only upon contact with an 
32 
  
aqueous solution. PCL films on their own exhibit an elastic modulus of 0.06 ± 0.04 MPa 
(assessed by traction test). 
The deposition of aligned piezoelectric and PCL fibers was performed by 
electrospinning. The silicon substrates deposited with PVA and PCL were fixed in a rotating 
collector for the deposition of aligned fibers. Relatively to the piezoelectric fibers, a solution of 
PVDF (70:30 w; Solvay) dissolved in methylethylketone (Labor Spirit) was electrospun 
(voltage: 10-12 kV; polymer solution concentration: 20% w/v; tip to collector distance: 12 cm; 
injection rate: 2 mL/h; relative humidity: 40-50% at room temperature (RT); collector’s rotation 
speed: 2000 rpm; collection time: 4 min.). Fibers with a diameter of 1.24 ± 0.13 µm were 
obtained. Piezo patches exhibit an elastic modulus of 5.08 ± 0.82 MPa. Concerning PCL fibers, 
a PCL solution (25% w/v, Aldrich) dissolved in Formic Acid/Acetic Acid (60/40) was electrospun 
using the same parameters as for the piezoelectric fibers except for the tip to collector distance 
(approximately 13 cm) and voltage: 23 kV. 
6.3. Surgical Induction Of Myocardial Infarction And Patch Fixation Procedure 
MI was experimentally induced by means of permanent ligation of the Left Anterior 
Descending (LAD) coronary artery, as previously described [174], with slight alterations. 
Firstly, buprenorphine (0.08 mg/kg; Bupaq; Richter Pharma) was administered 
intraperitoneally (ip) for analgesia purposes. Mice were then anesthetized by ip injection of a 
solution of ketamine (75 mg/kg, Clorketam; Vétoquinol) and medetomidine (1 mg/kg, 
Sededorm; ProdivetZN) and subsequently hydrated, via subcutaneous injection, with 1 mL of 
a Ringer’s lactate solution (B. Braun). Animals were mechanically ventilated with a small-
animal respirator (Minivent 845; Harvard Apparatus) coupled to an endotracheal tube. With the 
support of a stereomicroscope (Olympus SZX 10; Olympus), mice were submitted to a left 
thoracotomy on the third intercostal space, exposing the heart. The pericardial sac was gently 
disrupted and the first portion of the LAD artery (a pulsating bright red vessel positioned close 
to the left atrium) was ligated by passing a non-absorbable 7/0 suture (Silkam; B. Braun) under 
the artery and then knotting, permanently occluding the vessel. 
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Patches were immersed beforehand in a 1% Penicillin/Streptomycin (P/S) solution 
(100 U/ml Penicillin and 100 μg/ml Streptomycin, Labclinics) to facilitate their detachment from 
the silicon substrates, while avoiding bacterial contamination. Prior to surgery, the patches 
were detached from the substrates, using forceps and fine scissors, and placed over a PBS 
solution in a Petri dish. Immediately following LAD artery ligation, the infarcted area of the LV 
was further exposed. Subsequently, the floating patches were placed on the extremity of a 
biopsy punch (Ø – 4.0 mm) (BPP-40F; kai medical), positioning the fiber-containing side of the 
patch outwards. In parallel, a two-component fibrin glue (F007; zedira GmbH), extracted from 
porcine plasma, was prepared in an hydrophobic surface (Parafilm M®) by mixing 20 μL of 
component 1 (fibrinogen concentrate, 49-55 mg/mL) with 1 μL of component 2 (thrombin, 18-
20 NIH units/mL) in order to initiate polymerization and hydrogel/glue formation. Subsequently, 
patches were quickly immersed in the fibrin glue and, using the biopsy punch as a support, the 
patches were fixed by establishing contact with the epicardium of the exposed infarcted 
myocardium, aiming to orient the Piezo patch fibers in an oblique manner. To promote patch 
adhesion, the fibrin glue was allowed to polymerize for 20 seconds while the patches were 
pressed against the epicardium. During that period, gauze was applied in the edges of the 
intercostal incision to reduce fibrin glue spillage into the thoracic cavity. Thereafter, the biopsy 
punch was detached from the patch, and the unattached borders of the patch were removed 
with fine scissors. 
Intercostal and skin incisions were closed by an absorbable 6.0 suture (Safil, B. 
Braun) and surgical staples, respectively. Anesthesia was reversed by ip injection of 
atipamezole (5 mg/kg, Revertor; Virbac). Analgesia and fluid therapy were performed by ip 
administration of buprenorphine (0.08 mg/kg; Bupaq; Richter Pharma) and subcutaneous 
injection of 1 mL of a Ringer’s lactate solution (B. Braun), respectively. This procedure was 
repeated every 12 hours up to 72 hours after surgery or until full recovery. 
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6.4. Functional Characterization 
6.4.1. Echocardiography 
At 30 days post-MI, animals were subjected to transthoracic echocardiography by 
using the VEVO® 2100 system (Visual Sonics) coupled to a 40-MHz probe. Anesthesia was 
induced by placing the animals in an induction chamber filled with 5% isoflurane (IsoVet®, 
Braun) until loss of body posture and paw withdrawal reflex were confirmed. Thereafter, mice 
were transferred to a warm platform (at 37ºC) and placed in the left lateral decubitus position. 
Anesthesia state was maintained using a face mask (1.5% isoflurane) and, in order to measure 
heart rate (HR) and respiratory rate, their paws were placed over sensors that were in contact 
with an electroconductive gel, while body temperature was monitored by means of a rectal 
probe. Two-dimensional (2D) images were acquired of both short-axis (SAX) and parasternal 
long-axis (PSLAX) views. In SAX view, these were required to properly position the Motion-
mode (M-mode) cursor so that the dimensions of the LV cavity and LV walls (at systole and 
diastole) could be measured. PSLAX view images allowed to determine cardiac output (CO), 
i.e. the volume of blood pumped every minute, by measuring the diameter of the ascending 
aorta (by positioning the M-mode cursor at the level of the aortic walls) and the blood flow 
through this vessel by resorting to the Pulsed Wave Doppler (PW Doppler) mode. 
Several parameters were determined from the performed measurements. The LV 
internal diameter during diastole (LVIDd) and systole (LVIDs), obtained in SAX view in M-mode, 
were used to calculate the fractional shortening (FS) (i.e. the fraction of any diastolic dimension 
that is lost in systole): 
𝐹𝑆(%) =
𝐿𝑉𝐼𝐷𝑑 − 𝐿𝑉𝐼𝐷𝑠
𝐿𝑉𝐼𝐷𝑑
× 100    (𝐸𝑞. 1) 
and the LV volume during diastole (LVVOLd) or systole (LVVOLs) using the Tiecholz 
formula: 
𝐿𝑉𝑉𝑂𝐿𝑑/𝑠 =
7
2.4 + 𝐿𝑉𝐼𝐷𝑑/𝑠
  (𝐸𝑞. 2) 
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that, in turn, were required to calculate the ejection fraction (EF) (i.e. the fraction of 
the blood pumped from the heart at each heartbeat): 
𝐸𝐹 (%) =
𝐿𝑉𝑉𝑂𝐿𝑑 − 𝐿𝑉𝑉𝑂𝐿𝑠
𝐿𝑉𝑉𝑂𝐿𝑑
× 100.  (𝐸𝑞. 3) 
Furthermore, LVIDd, LV posterior wall thickness (LVPW), and LV anterior wall 
thickness (LVAW) (measured in SAX view) were used to estimate LV mass: 
𝐿𝑉 𝑚𝑎𝑠𝑠 = 0.8 × [1.053 × ([𝐼𝑉𝑆 (𝑜𝑟 𝐿𝑉𝐴𝑊) + 𝐿𝑉𝐼𝐷𝑑 + 𝐿𝑉𝑃𝑊]
3 − 𝐿𝑉𝐼𝐷𝑑
3)].   (𝐸𝑞. 4) 
The ascending aorta diameter, or LV outflow tract diameter (LVOT), and the velocity-
time integral of the aortic flow (VTI) (measured in PW Doppler mode), allowed the calculation 
of the stroke volume (SV) (i.e. the volume of blood pumped at each heartbeat): 
𝑆𝑉 = 0.785 × 𝑉𝑇𝐼 × 𝐿𝑉𝑂𝑇2  (𝐸𝑞. 5) 
that, in turn, in combination with the HR, was required to determine the CO: 
𝐶𝑂 = 𝑆𝑉 × 𝐻𝑅.   (𝐸𝑞. 6) 
Epicardial areas in systole and diastole (EPIareas and EPIaread, respectively), and 
endocardial areas in systole and diastole (ENDOareas and ENDOaread) were measured in the 
SAX view images, being the latter two used to calculate the endocardial fractional area change 
(EndoFAC): 
𝐸𝑛𝑑𝑜𝐹𝐴𝐶(%) =
𝐸𝑁𝐷𝑂𝑎𝑟𝑒𝑎𝑑 − 𝐸𝑁𝐷𝑂𝑎𝑟𝑒𝑎𝑠
𝐸𝑁𝐷𝑂𝑎𝑟𝑒𝑎𝑑
× 100.  (𝐸𝑞. 7) 
6.4.2. Electrocardiography 
Electrophysiological parameters were assessed at 30 days post-MI by means of 
surface ECGs. Firstly, mice were anesthetized as described for echocardiography. Then, 
animals were placed in supine position in a stable platform. ECG signals were obtained using 
a data acquisition hardware (PowerLab 8/35; ADInstruments) coupled to a signal amplifier 
(Animal Bio Amp; ADInstruments) and ECG electrodes, with the support of the LabChart 8 
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software (ADInstruments). The equivalent of a lead II configuration was used to obtain the 
ECG signals. 
Using an ECG analysis module, several parameters were measured: RR Interval, HR, 
PR Interval, P Duration, QRS Interval, QT Interval, JT Interval, T-peak to T-end interval, the 
amplitudes of P, Q, R, S and T waves and the ST segment height. Furthermore, QT corrected 
for the HR (QTc) was calculated through the Bazett’s formula: 
𝑄𝑇𝑐 =
𝑄𝑇
√𝑅𝑅 𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙
 .  (𝐸𝑞. 8) 
6.5. Histological Procedures And Immunohistochemistry 
At 0, 2, 3, 7 and 30 days after surgery, animals were deeply anesthetized by ip 
injection of solution of ketamine (75 mg/kg, Clorketam; Vétoquinol) and medetomidine (1 
mg/kg, Sededorm; ProdivetZN). After 4M potassium chloride (Sigma-Aldrich) injection, 
diastole-arrested hearts were harvested and washed in PBS. Macroscopic photographs of the 
hearts were obtained using a stereomicroscope (Olympus SZX 10; Olympus) coupled to a 
camera (Olympus DP21; Olympus). 
Hearts were fixed in 10% (v/v) neutral buffered formalin (Prolabo; VWR International) 
for approximately 16 hours at RT. Prior to paraffin embedding, hearts were submitted to an 
automated histological processing in a paraffin tissue processor (Microm STP 120-2; Thermo 
Scientific) in which the samples are immersed in the following solutions, for a total of 12 hours: 
phosphate buffered saline (PBS), crescent series of alcohols (from 70% to absolute) (Aga), 
Clear Rite 3® (Thermo Scientific) and paraffin (Histoplast Paraffin; Thermo Scientific) at 56ºC. 
Following histological processing, hearts were embedded in paraffin blocks in a modular 
paraffin embedding system (Microm EC-1/2; Thermo Scientific). 
Paraffin-embedded hearts were sectioned transversally (microtome RM2255; Leica) 
from the apex to the base accordingly to [175]. In order to achieve a representative sampling 
of the LV, 3 μm-thick sections were obtained from equidistant regions (300 μm) of the LV (in a 
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total of, approximately, 15 sections per heart). In order to assess the presence of the patches 
at early timepoints (0 to 7 days after surgery) and to perform morphometric analysis/infarct 
size quantification, the paraffin sections were stained with Hematoxylin-Eosin (HE) or modified 
Masson’s Trichrome (MT), respectively. Sections were dewaxed using xylene and hydrated by 
a descending series of ethanol prior to both HE and MT stains. For the HE stain, paraffin 
sections were immersed for 5 minutes in Gill’s Hematoxylin (GHS232, Sigma-Aldrich) and 
washed for 2 minutes with tap water. Sections were then dehydrated by an ascending series 
of ethanol and incubated for 2 minutes in alcoholic eosin (Leica & Thermo). MT stain was 
performed according to the Trichrome (Masson) Stain kit (Sigma-Aldrich), except for the 
following alterations: nuclei were prestained with Celestine Blue solution prior to Gill’s 
Hematoxylin stain, followed by a 1-hour incubation in aqueous Bouin’s solution (HT10132-1L, 
Sigma-Aldrich) in order to promote an uniform staining. Following either HE or MT stains, the 
sections were diafanized in xylene and mounted in Entellan® mounting medium (107960, 
Merck Millipore). Whole-section low-magnification images were acquired with a 
stereomicroscope (Olympus SZX 10; Olympus) coupled to a camera (Olympus DP21, 
Olympus), while high-magnification images were acquired using an optical microscope 
(Olympus CX31, Olympus) coupled to a camera (Olympus DP21, Olympus) or by means of a 
digital slide scanner (NanoZoomer 2.0-HT, Hamamatsu). 
For immunostainings, sections were subjected to dewaxing and hydration. Antigen 
retrieval of masked epitopes, which is frequently required in formaldehyde-fixed tissues in 
order to allow an efficient antibody-antigen binding, was executed for some of the assessed 
antigens (Table 2). Then, since assessed antigens were located in the cytoplasm, heart tissue 
sections were permeabilized with 0.2% Triton X-100 (Sigma-Aldrich). Since we used primary 
antibodies that were produced in mouse, the Vector M.O.M.™ kit (BMK-2202, Vector 
Laboratories) was applied to block endogenous mouse immunoglobulins of the tissue, which 
could bind to the secondary antibodies and, ultimately, lead to unspecific stainings [176]. 
Sections were incubated with primary antibodies (Table 2) overnight at 4ºC, in a humidified 
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chamber. Thereafter, incubation with secondary antibodies (Table 3) was performed for 1 hour 
at room temperature (RT). Lastly, sections were mounted with Fluoroshield™ with DAPI 
(F6182, Sigma-Aldrich). Images were acquired with an inverted fluorescence microscope 
(Leica DMI 6000B FRET, Leica Microsystems) coupled to a camera (Leica DFC360 FX, Leica 
Microsystems). 
Table 2 - List of primary antibodies used along with their respective working dilution and antigen 
retrieval. 
Primary Antibody (Isotype) Reference Dilution Antigen Retrieval 
α-sarcomeric actin 
(Mouse IgM) 
A2172, Sigma 1:500 None 
α-smooth muscle actin 
(Mouse IgG) 
A5228, Sigma 1:750 10 mM Sodium Citrate Buffer pH=6.0 
(35 min. 98ºC water bath + 20 min. RT) 
CD45 
(Goat IgG) 
AF114, R&D 1:50 10 mM Sodium Citrate Buffer pH=6.0 
(35 min. 98ºC water bath + 20 min. RT) 
Connexin 43 
(Goat IgG) 
AB0015-200, SICGEN 1:100 None 
 
Table 3 - List of secondary antibodies used along with their respective working dilution 
Secondary Antibody Reference Dilution 
Alexa Fluor® 488 Donkey anti Goat IgG A-11055, Thermo Fischer Scientific 1:1000 
Alexa Fluor® 488 Donkey anti Mouse IgG A-21202, Invitrogen 1:1000 
Alexa Fluor® 568 Donkey anti Goat IgG A-11057, Invitrogen 1:1000 
Goat anti Mouse IgM-Texas Red sc-2983 1:1000 
6.6. Piezoelectric Fibers Orientation Scoring  
Since piezoelectric materials originate electric currents in an anisotropic fashion we 
assessed their orientation. One representative Masson’s Trichrome stained section of each 30 
days post-MI (dpmi) heart of the Piezo group was selected for scoring and several high 
magnification images (fields with approximately 94 556 μm2 each) were acquired along the 
region of the implantation site. Four fields from separate regions were selected. A total of 
randomly selected 100 fibers (25 per field) were scored for each heart and, in order to reduce 
subjectivity, the scoring was performed by two operators, each one scoring 2 fields per heart. 
A score was assigned for each analyzed fiber, ranging from score I (transverse orientation) to 
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IV (longitudinal orientation). Scoring was mainly based on length measurement: score I - 
directly assigned to fibers that had a clear transverse orientation or that exhibited a length 
inferior or equal to 0,9 μm; score II -  0,9 μm < fiber length ≤ 12 μm; score III - 12 μm < fiber 
length ≤ 24 μm; score IV – fiber length > 24 μm. 
6.7. Measurement Of Myocardial Infarct Size And Morphometric Analysis 
To determine infarct size, deposited collagen, which becomes stained blue when 
subjected to MT staining, was used to define the LV scarred region. The stereomicroscope-
acquired low magnification images of the MT-stained histological sections were analyzed using 
the semiautomated software MIQuant, a tool previously developed by our team [177]. This 
software determines the percentage of ischemic LV wall by two distinct methods: area 
measurement [174] and midline length [178]. Additionally, scar volume was calculated as 
previously described [179]. First, scar volume between serial histological sections was 
obtained by using the formula of the volume of a truncated pyramid and then total scar volume 
was calculated by the sum of the latter: 
𝑇𝑜𝑡𝑎𝑙 𝑆𝑐𝑎𝑟 𝑉𝑜𝑙𝑢𝑚𝑒 = ∑  
1
3
𝑑(𝐴𝑖 + 𝐴𝑖+1 + √𝐴𝑖 × 𝐴𝑖+1)
𝑁−1
𝑖=1
    (𝐸𝑞. 9) 
Ai and Ai+1 are the infarcted areas obtained by MIQuant of section number i and the 
subsequent one in the series, respectively; d is the distance between sections (which in this 
case is 0.300 mm); and N is the number of sections analyzed. Simillarly, the data obtained 
from MIQuant concerning the midline length was used to estimate the total scar surface area 
at the midline position, resorting to the formula of the truncated pyramid lateral surface area: 
𝑇𝑜𝑡𝑎𝑙 𝑆𝑐𝑎𝑟 𝑀𝑖𝑑𝑙𝑖𝑛𝑒 𝐴𝑟𝑒𝑎 = ∑
𝑀𝑖 + 𝑀𝑖+1
2
√(𝑅𝑖 − 𝑅𝑖+1)2 + 𝑑2
𝑁−1
𝑖=1
  (𝐸𝑞. 10) 
Mi and Mi+1 are the midline lengths of the infarcted region obtained by MIQuant of the 
section number i and the subsequent one in the series, respectively; Ri and Ri+1 are the LV 
radius at the midline position, assuming the midline path as a circumference; d is the distance 
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between sections which, in this case, is 0.300 mm; and N is the number of sections analyzed. 
The same calculations (volume and midline area) were performed for the total LV in order to 
calculate percentage of ischemic wall through these parameters. Morphometric analysis was 
executed by using the Image J software (NIH). LV wall thickness was determined on regions 
that exhibited collagen deposition in 50% or more of the wall and calculated as the average of 
the distance across the wall of five equidistant points of the ischemic wall. LV dilation was 
assessed by the lumen-area percentage, i.e. the ratio between the lumen area delimited by 
the endocardium and the total LV area. Area of myocardium within the infarcted regions was 
quantified. The area of the cell infiltrate surrounding the patches was calculated as the average 
of infiltration areas in subsequent serial sections. The volume of the inflammatory mass was 
calculated by applying Eq. 9. 
6.8. Statistical Analysis 
Values presented in text and figures are mean ± standard error of the mean (SEM). 
Data statistical analysis was performed with the IBM SPSS Statistics 21 software. Shapiro-
Wilk’s test was used to evaluate if the data displayed a normal distribution. If so, the 
homoscedasticity of the data was tested by Levene’s test. These results defined the statistical 
test(s) used further. Normal distributed and homocedastic data were tested with parametric 
tests (independent samples t-test). Non-normal distributed and/or heterocedastic data were 
tested with non-parametric tests (Mann-Whitney U Test). The statistical significance level 
chosen for all statistical tests was p<0.05. 
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Figure 10 - Schematic representation of the main experiment methodology 
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7. RESULTS  
7.1. Optimization And Implementation of Surgical Fixation of The Patch 
Aiming to evaluate the therapeutic potential of the Piezo patches, a patch fixation 
procedure was implemented at our laboratory. For ethical and practical reasons, prior to its 
evaluation 30 dpmi in a substantial number of animals, the procedure was optimized 
beforehand at earlier timepoints. Hence, the following criteria had to be fulfilled and tested: 1) 
the patch had to remain adhered to the epicardium for several days; and 2) the patch had to 
be placed in a manner that allowed it to be deformed in a cyclic fashion and in synchrony with 
the myocardial activity; 3) the duration of the patch fixation should not extend significantly the 
surgical procedure. 
Since patch fixation to the heart by sutures is commonly used in rat models [180-182], 
in the first application attempts, the Piezo patches were sutured to the epicardium (Figure 11A, 
B). Sutures were performed on two opposite sites, being attempted two different patch 
configurations: 1) a spread patch (Figure 11A); or 2) a stretched bundle patch (Figure 11B). In 
both situations the patch was not sufficiently stretched so, although the patch was fixed to the 
epicardium at the sutured sites, the remaining portion was wrinkled and was not in direct 
contact to the myocardium. Following this outcome, we hypothesized whether fully spread 
patches directly glued to the epicardium would allow a closer contact with the myocardium. To 
test this hypothesis, the effect of fibrin glue was assessed. Fibrin glue has been widely used 
as a tissue sealant in animal in vivo studies and clinical applications (reviewed on [183]), 
including in a study where a patch was successfully applied to a murine heart following MI 
[184]. Furthermore, in order to allow the patches to be stretched upon application, a biopsy 
pen was used (Figure 11C). The biopsy pen also allowed the piezo patches to be oriented 
since fiber orientation was visible under a stereomicroscope (Figure 11D), and provided a 
physical support upon patch placement (Figure 11E). This patch placement method allowed 
the patch to be stretched and closely adhered to the epicardium, being deformed 
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synchronously with the heart cycle (Figure 11F). Of note, gauze was applied in the incision 
border below the patch (Figure 11E) to avoid spillage of fibrin glue into the thoracic cavity, 
since we observed that the organs of the thoracic cavity could become severely adhered to 
each other if caution was not taken (not shown). 
To assess whether the patches remained adhered to the epicardium after surgery, 
hearts were harvested in the first 24 hours following surgery (0 dpmi) for histological analysis. 
Macroscopic images of the harvested hearts show clearly that the patch remained adhered to 
the hearts at the infarcted region (below the ligation site) in both Piezo (Figure 11G, I) and PCL 
groups (Figure 11J, L). Furthermore, histology showed that the PVDF-TrFE fibers of the Piezo 
patches are visible, exhibiting a translucent appearance (Figure 11H, arrow heads), and in 
close contact to the myocardium. Conversely, PCL fibers were not detectable by histology 
(Figure 11K). Nevertheless, in both groups an acellular layer juxtaposed to the myocardium 
was observed under the microscope (Figure 11H, K, #), possibly fibrin glue. Having confirmed 
the presence of the piezoelectric fibers at the first 24 hours after surgery, we analyzed the 
hearts of the Piezo group at later timepoints: 2, 3 and 7 dpmi. Histological analysis revealed 
that the piezoelectric fibers were present at the considered timepoints in the proximity of 
cardiomyocytes (Figure 11M, N, O, arrow heads). Of note, at 7 dpmi piezoelectric fibers were 
surrounded by cells which morphologically resembled inflammatory cells Figure 11-O, *). 
Following establishment of the surgical patch fixation, a proof-of-principle experiment 
was designed and initiated (Figure 10) to evaluate the histo-physiological impact of a 30-day 
Piezo patch delivery to an infarcted mouse heart. Overall the duration of the surgical procedure 
was ~20 minutes and patch fixation efficiency, i.e. the percentage of patches successfully 
applied relatively to the total of patch placement attempts, was ~78% for PCL patches and 
~80% for the Piezo counterparts. Furthermore, the survival rate at 30 dpmi was 33.37% (Figure 
12) and 76.64% of the deaths occurred in the first 24 hours (Figure 12). 
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Figure 11 - Implementation and Optimization of the patch surgical fixation. (A and B) - Suture-based 
patch placement, including spread patch (A) and bundle (B) configurations; inset: 2x magnification of 
the implantation site. (C and D) - Biopsy punch showing clear fiber orientation of a Piezo patch (D). (E 
and F) -  Patch fixation procedure with a biopsy punch and fibrin glue, while using gauze to reduce fibrin 
glue spillage into the thoracic cavity (E), resulted in an adhered and properly stretched patch (F). (G, I, 
J and L) – Macroscopic images of hearts subjected to MI and Piezo (G and I) or PCL patch delivery (J 
and L) revealed that patches (outlined in dashed line) remain adhered at least during the first 24 hours 
post-MI (0 dpmi) (n=4 for each group). Scale bars: 2 mm. (H and K) – Representative images of HE-
stained sections of hearts 24 hours after Piezo (H) or PCL (K) patch fixation. Fibrin glue is visible in both 
groups (#) but polymeric fibers are only visible in the Piezo group (arrow heads). Scale bars: 20 μm. (M 
to O) Representative images of HE-stained sections of hearts 2 (M, n=2), 3 (N, n=1) and 7 days (O, 
n=1) after Piezo patch implantation. Fibers were visible at all timepoints (arrowheads) and a cell infiltrate 
around Piezo fibers was detected at 7 days (*). Scale bars: 20 μm. 
 
 
 
 
Figure 12 – Animal survival. Kaplan-Meier 
Survival Curve for the 30 days elapsed after 
patch placement procedure in both Piezo and 
PCL groups.  
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7.2. Functional Characterization 
In order to assess functional proficiency, animals were subjected to transthoracic 
echocardiography at 30 dpmi and several parameters were determined (Table 4). Although 
not statistically different, most analyzed echocardiographic parameters showed a tendency for 
improved LV systolic function in the Piezo patch group (Figure 13A-E and Table 4). The 
average of left ventricular internal diameter during diastole (LVIDd) was increased over 10% 
in the PCL group relatively to the Piezo group (Figure 13A, B and Table 4) suggesting an 
aggravated LV cavity dilation in the former. Moreover, there were evidences of improved LV 
systolic function in the Piezo group since displayed increased fractional shortening (FS) and 
ejection fraction (EF) when compared to the PCL counterparts (Figure13C, D and Table 4). 
Interestingly, cardiac output (CO) was increased in the PCL group (Figure 13E, F and Table 
4), owing both to an augmented heart rate and stroke volume (Table 4).  
 
Table 4 – Echocardiographic parameters obtained in both Piezo and PCL groups. 
Echocardiographic 
Parameters 
Piezo Group(mean ± SEM) 
n=5 
PCL Group (mean ± SEM) 
n=6 
SAX LVIDd (mm) 4,392 ± 0,243 5,007 ± 0,258 
SAX LVIDs (mm) 3,684 ± 0,296 4,408 ± 0,330 
SAX FS (%) 16,41 ± 2,82 12,26 ± 3,20 
SAX EF (%) 33,97 ± 5,28 25,55 ± 6,39 
HR (bpm) 370 ± 15 411,3 ± 18,75 
VTI (mm) 19,55 ± 1,93 17,79 ± 2,26 
LVOT (mm) 1,314 ± 0,045 1,448 ± 0,0168 
SV (μL) 26,91 ± 4,00 29,40 ± 4,00 
CO (mL/min.) 9,828 ± 1,356 12,00 ± 1,634 
ENDOarea;d (mm2) 13,89 ± 1,80 19,28 ± 2,24 
ENDOarea;s (mm2) 11,23 ± 1,78 13,71 ± 2,11 
EndoFAC (%) 13,10 ± 1,77 18,58 ± 2,22 
SAX LV mass (mg) 122,5 ± 15,93 173,2 ± 9,80 
SAX LVAWd (mm) 0,7800 ± 0,1083 0,9767± 0,0733 
SAX LVPWd (mm) 0,9500 ± 0,1281 0,9617 ± 0,1319 
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Figure 13 – Functional characterization by transthoracic echocardiography. (A) Representative M-mode 
images of SAX view of both Piezo (left) and PCL (right) groups, at 30 dpmi. (B to E) LV internal diameter 
during diastole (LVIDd) (B), ejection fraction (EF) (C) and fractional shortening (FS) (D) revealed 
functional improvements in the Piezo group although without statistical significance. Cardiac output (CO) 
was increased in the PCL group (E). Values are mean±SEM. n(Piezo)=5, n(PCL)=6. 
The effect of the Piezo patches on cardiac electrical conduction was assessed by 
surface ECGs. ECG morphology of the PCL group was clearly more disrupted than in the Piezo 
group (Figure 14A). Table 5 summarizes the obtained electrophysiological parameters. 
Notably, the QRS complex of the Piezo group was narrower than in the PCL group (Figure 
14B and Table 5), suggesting an improvement in ventricular electrical activation on the former. 
Strikingly, the PCL group exhibited markedly prolonged JT and Tpeak to Tend intervals 
relatively to Piezo counterpart, with the latter parameter being statistically different between 
groups (p<0,05). Both of these parameters highly indicate that the Piezo group has a more 
efficient ventricular repolarization. As expected, the values of said parameters culminated in a 
decreased QTc interval in the Piezo group when compared to the PCL counterpart (Figure 14E 
and Table 5). Piezo group also showed an almost neutral Q amplitude, which contrasted to the 
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abnormally increased negative value observed in the PCL group, and a significantly increased 
R amplitude (Figure 14A, F and G and Table 5), Collectively, these results strongly suggest 
that the Piezo group has a decreased risk of ventricular arrhythmias, associated with improved 
ventricular electrical integrity. 
 
Table 5 - ECG parameters obtained in both Piezo and PCL groups 
ECG 
Parameters  
Piezo Group (mean ± SEM) 
n=5 
PCL Group (mean ± SEM) 
n=6 
RR Interval (ms) 129,1 ± 7,7 118,7 ± 2,5 
HR (bpm) 472,3 ± 25,0 508,4 ± 10,5 
QRS Interval (ms) 9,637 ± 0,869 13,75 ± 2,15 
JT Interval 7,783 ± 2,881 31,20 ± 10,80 
Tpeak to Tend Interval (ms)1 4,343 ± 1,409 16,000 ± 4,579 
QT Interval (ms)1 17,73 ± 3,91 45,31 ± 12,33 
QTc Interval (ms)1 50,05 ± 10,55 131,20 ± 34,23 
ST height -0,06316 ± 0,02085 0,02130 ± 0,09218 
P duration 25,90 ± 12,22 23,90 ± 5,13 
P amplitude 0,05285 ± 0,04558 0,08919 ± 0,02811 
Q amplitude2 0,02613 ± 0,03697 -0,5002 ± 0,1495 
R amplitude1 0,8580 ± 0,08783  0,5172 ± 0,1136 
S amplitude -0,3963 ± 0,09222 -0,3210 ± 0,1289 
T amplitude 0,1334 ± 0,06453 0,04487 ± 0,02423 
1 – p<0.05;2 – p<0.01 
7.3. Cardiac Tissue Response and Remodeling 
Having the animals been functionally characterized 30 dpmi, heart were harvested and 
processed for histological analysis. Firstly, the presence of the patch and the tissue response 
originated from their implantation was assessed. In both experimental groups, an extensive 
cellular infiltrate was observed in the implantation site (Figure 15A-C, F-H, *), similar to what 
was observed 7 dpmi in the Piezo group (Figure 11O, *). Interestingly, blood vessels (Figure 
15K) and, apparently, multinuclear cells were detected within the cell mass (Figure 15K, arrow 
head).The area occupied by this cellular infiltrates was increased in the Piezo group (area: 
0,8275 ± 0,205 mm2, volume: 1,817 ± 0,553 mm3; n=5), relatively to the PCL group (area: 
0,5243 ± 0,107 mm2, volume: 0,7613 ± 0,154 mm3; n=6) (Figure 15D,E). Furthermore, note 
that the cells from the patch region were not in direct contact with the myocardium, being the 
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interface composed of collagen fibers (Figure 15C and H, #). Polymer-based fibers, only visible 
in Piezo group, were intermingled with the cellular infiltrate at a density of 2922 ± 136 
fibers/mm2 and were not in direct contact with cardiomyocytes (Figure 15C, inset, arrow 
heads). Most piezoelectric fibers showed a nearly-transverse orientation (Figure 15I) and, as 
observed at early timepoints, fibers were translucent (Figure 15J-L). 
 
Figure 14 – Functional characterization by electrocardiography. (A) Representative ECG signal samples 
of Piezo (top) and PCL (bottom) groups. J point and P, Q, R and S waves are indicated in the first cycle. 
A clear disruption in the QRS complex is observed in t in the PCL group. (B to G) QRS interval and JT 
interval show clear tendencies to be increased in the PCL group, while QTc interval, Tpeak to Tend 
interval, R and Q amplitudes revealed statistically significant improvements in cardiac conduction on the 
Piezo group. Values are presented as mean ± SEM. n(Piezo)=5, n(PCL)=6. *p<0,05; **p<0,01. 
To assess whether the Piezo patches had an effect on cardiac remodeling, i.e. in LV 
wall thinning and non-contractile collagen-rich scar tissue formation, morphometric analysis of 
representative LV histological sections was performed in both groups (Figure 16). Infarct size, 
as assessed by infarct area (29,95 ± 4,04 % in the Piezo group vs 32,69 ± 4,06 % in the PCL 
group; n=5 and n=6, respectively), volume (21,70 ± 1,79 % in the Piezo group vs 22,26 ± 2,10 
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% in the PCL group; n=5 and n=6, respectively), midline length (36,32 ± 4,11 % in the Piezo 
group vs 40,46 ± 4,83 % in the PCL group; n=5 and n=6, respectively) and midline area (36,95 
± 4,50 % in the Piezo group vs 44,02 ± 7,07 % in the PCL group; n=5 and n=6, respectively), 
was similar in both groups (Figure 16B). Furthermore, although no statistical differences were 
found on the LV free wall thinning (596,5 ± 54,42 μm in the Piezo group vs 541,9 ± 46,04 μm 
in the PCL group; n=5 and n=6, respectively) (Figure 16C) and LV chamber dilation (24,95 ± 
2,93 % in the Piezo group vs 27,27 ± 3,57 % in the PCL group; n=5 and n=6, respectively) 
across groups (Figure 16D), PCL group displayed a small tendency for aggravated remodeling. 
Interestingly, the PCL exhibited extended regions of myocardial tissue within the infarcted zone 
(7,784 ± 1,915 % in the Piezo group vs 9,266 ± 0,8146 % in the PCL group; n=5 and n=6, 
respectively) (Figure 16E), however the degree of viability and contractility of this tissue was 
not determined .
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Figure 15 – Tissue response to patch implantation. (A to H) - High-resolution whole-section images of representative Masson’s Trichrome stained sections 
of hearts at 30 dpmi of both Piezo (A and B) and PCL (F and G) revealed the presence of an cell extensive cell infiltrate at the implantation site, mainly 
composed of cells with a macrophage-like morphology (C and H, *), that is separated from the myocardium by collagen fibers (blue colored) (C and H, 
#). Polymeric fibers are only visible in the Piezo group (C, arrow heads). The extent of the cellular infiltrate appears to be increased in both area (D) and 
volume (E) on the Piezo group. Scale bars: A and F – 2 mm, B and G - 500 μm, C and H – 50 μm. (I) Histogram representing the scoring of the orientation 
of piezoelectric fibers relative to the sectioning cut showing a clear tendency for transversal orientation. (J to L) – Piezoelectric fibers show a translucent 
appearance and are often surrounded by macrophage-like multinucleated cells (arrow head) and in the vicinity of perfused vessels (K). Scale bars: J – 
50 μm, K and L - 20 μm. Values are presented as mean ± SEM. n(Piezo)=5, n(PCL)=6 
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Figure 16 - – Effect of the Piezo patch on cardiac remodeling. (A) Representative Masson’s Trichrome-stained histological sections of the LV from 
the apex (top left) to the base (bottom right) of Piezo (top) and PCL (bottom) groups at 30 dpmi. Scar tissue is clearly visible in blue, contrasting with 
the red-stained myocardium. Scale bar: 2 mm. (B to E) Infarct size (calculated by infarct area, infarct volume, midline length and midline area) (B), 
LV free wall thickness (C) and LV cavity dilation (D) showed slight tendencies in favor of the Piezo group, although the PCL group present increased 
proportion of CMs within the scar tissue (E). Values are presented as mean ± SEM. n(Piezo)=5, n(PCL)=6. 
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7.4. Protein Expression at The Patch-Myocardium Interface 
In order to further characterize the tissue response to the patch, immunofluorescence was 
performed. Considering that the histological characterization revealed the presence of an extensive 
cell infiltrate on the implantation site and surrounding piezoelectric fibers (in the Piezo group), we 
explored if this was part of an inflammatory reaction to the patch by assessing the presence of 
hematopoietic cells (that, except for mature erythrocytes, express CD45, a membrane glycoprotein). 
Additionally, the expression of α-smooth muscle actin (αSMA), expressed in smooth muscle cells and 
in myofibroblasts, was assessed at the patch-myocardium interface. In both groups, the cell infiltrate 
at the implantation site was rich in CD45-expressing cells (Figure 17), when compared to adjacent 
scar and myocardial tissues (Figure 17B and D). Moreover, cells surrounding the piezoelectric fibers 
Figure 17A-C) were also CD45+. Of note, these CD45+ cells were big and multinucleated (Figure 17C, 
arrow heads), contrasting to small-sized CD45+ cells found in the myocardial border zone and scar 
region (Figure 17B). These aspects, in combination with histological observations (Figure 15), are 
indicative of macrophages and foreign body giant cells, which result from macrophage fusion in the 
context of foreign body reaction to a biomaterial. Additionally, these big and often multinucleated 
CD45+ cells were less abundant in the PCL group in which mainly small, round CD45+ were observed 
Figure 17D). Furthermore, αSMA-expressing cells sparsely distributed (apart from the blood vessel 
counterparts which were also present in this tissue) were detected in the vicinity of piezoelectric fibers 
(Figure 17C, arrows), suggesting the presence of myofibroblasts. 
Considering the marked improvement on cardiac conduction of the Piezo group, Cx43 
expression pattern was evaluated in both experimental groups, in combination with the alpha-
sarcomeric actin (α-SA) (a marker of sarcomeres which was used to detect CMs) to assess the 
localization of gap junctions in CMs (Figure 18). No relevant differences were detected in the 
expression levels or localization of Cx43 expression across groups (Figure 18) as, in both conditions, 
Cx43 expression pattern appeared equally disrupted in CMs of the peri-infarct zone (Figure 18B and 
E) when compared to CMs of the remote myocardium (Figure 18C and F) 
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Figure 17 – Inflammatory response on the patch-myocardial interface. Representative images of the Piezo (A 
to C) and PCL (D) at the patch-myocardium interface following immunofluorescence for αSMA (green) and 
CD45 (red). Piezoelectric fibers are highly autofluorescent and appear in bright orange-red (A, B and C). CD45-
expressing cells are abundant in the cell infiltrate surrounding the fibers, which contrasts with the adjacent 
myocardium in which the CD45+ cells are sparsely found. Large, multinucleated CD45+ cells were common 
within the cell mass (C, arrowheads). Sparsely distributed αSMA+ cells were present mainly in the cell mass of 
the Piezo group (C, arrows). CD45+ cells of the PCL group were smaller and rarely multinucleated (D). Dashed 
lines: interface between the patch region and the scar or myocardial tissue. Nuclei stained in blue (DAPI) Scale 
bars: A, B and D – 100 μm; C – 50 μm. αSMA - alpha-smooth muscle actin. 
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Figure 18– Effect of the Piezo patch on intercellular coupling. Representative images of Piezo (A to C) and PCL (D and F) groups, 
following immunofluorescence for Cx43 (green) and α-SA (red). Although, intercellular coupling appeared slightly disrupted in peri-
infarct and near the patch (B and E) when compared to remote myocardial regions (C and F), no apparent differences were detected 
between experimental groups. Nuclei stained in blue (DAPI). Scale bars: A and D – 200 μm; B, C, E and F – 20 μm. α-SA - alpha-
sarcomeric actin, Cx43 – connexin 43. 
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8. DISCUSSION 
CVDs are the leading cause of death in the industrialized world, being estimated that they 
are cause of approximately 17,4 million deaths per year, with an expected increase up to 23,6 million 
by the year 2030 [1]. These conditions are frequently associated with cardiac electrical disruption and 
the onset of arrhythmias [6] that, in turn, can be fatal. Considering the several drawbacks of the current 
gold-standard therapies for cardiac failure (e.g. heart transplant) and aiming to restoring cardiac 
electrical integrity (e.g. electronic pacemakers, implantable cardioverter devices) it is of paramount 
relevance to develop novel therapies that allow full restoration of cardiac function, by acting on cardiac 
tissue remodeling, contractility and electrical conduction capabilities. Although novel approaches 
involving cell therapy, injectable hydrogels or biomaterial-based cardiac patches (with or without cells) 
have been emerging, these are mainly focused on reducing the detrimental effects of fibrosis upon 
CVDs (reviewed on [19, 20]) rather than focusing on restoring cardiac electrical integrity. 
In the herein study, we aimed to test the in vivo effect, in a murine model of MI, of a patch 
comprising a film composed of PCL, a biocompatible and biodegradable polymer extensively used in 
biomedical applications [185-189] (including cardiovascular ones [190, 191]), with electrospuned 
PVDF-TrFE fibers with piezoelectric properties. Since piezoelectric materials accumulate electric 
charges upon mechanical deformation [192] we hypothesized that successive deformation cycles 
induced by the cardiac cycle would induce charge accumulation on the piezoelectric fibers, provoking 
the formation of electrical currents in synchrony with the heart rate and, ultimately, restore cardiac 
electrical conduction on a disease scenario. In vivo testing of these patches was prompted by 
preliminary in vitro work that showed that these Piezo patches sustain neonatal rat CM contractility 
for at least 12 days and induced an increased expression of functional Cx43 and relevant ionic 
channels on these cells (unpublished data, please see Preliminary Results) Additionally, these 
materials resulted in improved calcium cycling and induction of a more mature, aligned morphology 
(unpublished data). Herein, the in vivo effect was compared with a control group involving the use of 
PCL films with deposited PCL fibers. 
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In order to evaluate the in vivo effect of the Piezo patches we first implemented the patch 
surgical fixation in our laboratory (Figure 11). Although suturing methods have been commonly 
applied to fix patches to the epicardium of rat [180-182, 193], this approach was not efficient in our 
setting. On one hand, the delicate and flexible structure of the patch impaired handling and smooth 
perforation of the suture needle, extending significantly the surgery duration (not shown). And, on 
other hand, although the patches remained fixed to the heart during surgery with both spread and 
bundle configuration, the films were not in close contact with the epicardium and were not stretched, 
which is an essential prerequisite to allow the patch to properly suffer heart cycle-induced 
deformations and, ultimately, allow electrical current induction. Nevertheless, this issue was solved 
by resorting to a biopsy pen and porcine fibrin glue, being fibrin glue commonly used in several 
biomedical applications [183]. However, it should be referred that fibrin glue should be used with 
caution, as it could lead to severe adhesion between the organs [194]. Using this method, Piezo and 
PCL patches remained attached the heart at early time points despite the elevated heart rate of mice 
(~400 BPM), suggesting the feasibility of this patch placement method. Following establishment of 
the patch fixation method, a proof-of-principle experiment was initiated in which the patch effect were 
observed at 30 days post MI. The experimental survival rate was reduced (~33, 37%) when compared 
to mice uniquely subjected to MI [174, 195]. However this survival is in accordance with other models 
established at our laboratory, namely, cell intramyocardial injection after MI. Moreover, considering 
that more than 70% of the deaths occurred during the first 24 hours, this high mortality appears to be 
caused by the procedure itself rather than by patch-related effects. Indeed, the patch fixation is an 
invasive procedure that increases the duration of an open-chest surgery, which is a key parameter 
influencing animal survival [196]. 
Histological analysis at 30 days post-MI showed that piezoelectric fibers were abundant in 
the fixation site, with a similar aspect to early timepoint, thus showing that the patch persisted 
throughout the experiment and without any detectable fiber degradation. Conversely, the PCL fibers 
were not even observed at the first 24 hours, despite clear macroscopic evidences that the patch was 
yet in place. Whether this fact is due to much reduced fiber dimensions or due to degradation caused 
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by fixation and/or histological processing, it is unknown. Nevertheless, the fact that in both 
experimental groups, an extensive cell infiltrate of mainly CD45+ cells was visible at the implantation 
site (Figure 15 and Figure 17), supports the hypothesis that both patches remained adhered to the 
epicardium originating an exacerbated extra-cardiac inflammatory response. The cell infiltrate 
appeared surrounded by a fibrous capsule, being collagen fibers present at the interface between the 
infiltrate and the myocardium. In the Piezo group, this response likely evolved to a foreign body 
reaction as fibers were surrounded by CD45+ multinucleated cells (resembling foreign body giant 
cells, which originate from macrophage fusion), capillaries (typical of the granulation tissue), collagen 
fibers and the presence of sparsely distributed α-SMA+ cells which could possibly be myofibroblasts, 
which are commonly present on wound healing scenarios [197]. This type of tissue response was 
also obtained by others, where, for instance, a PCL fiber-based scaffold was sutured in the epicardium 
of a MI rat model [193]. The presence of giant multinucleated cells was less apparent in the PCL 
group, possibly due to the absence of fibers with substantial dimension. These results question the 
biocompatibility of the Piezo patches, as an exacerbated inflammatory reaction followed by a foreign 
body reaction could have detrimental effects on the cardiac function and attenuate the putative effects 
of the piezoelectric fibers, due to their foreign body reaction-induced isolation. Thus, one should 
evaluate the pros and cons of having non-degradable (at least for 30 days) piezoelectric fibers, which, 
on one hand, induce a foreign body reaction response but, on the other hand, only exhibit piezoelectric 
properties in an intact state. Notwithstanding, novel strategies to avoid biomaterial-related foreign 
body reaction are emerging [198, 199] and that could render the Piezo patches more biocompatible. 
Additionally, should be mentioned that this massive inflammatory response may not be uniquely 
originated from the patches themselves but, probably, by the invasive patch placement procedure 
and due to the application of fibrin glue. The latter comprises a component of the provisional matrix 
which it is formed early in the response to biomaterials and that modulates the subsequent 
inflammatory cell accumulation and, consequently, the extent of the inflammatory response [197]. 
In order to assess the in vivo effect of the Piezo patches, mice were functionally characterized 
by echocardiography (Figure 13) and ECG (Figure 14) at 30 dpmi. ECG assessment showed 
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statistically relevant differences, in favor of the Piezo group, on several parameters associated with 
ventricular conduction and the depolarization/repolarization processes (QTc interval, Tpeak to Tend 
interval, R amplitude and Q amplitudes), with the QRS interval and JT interval revealing clear 
tendencies. Decreased QTc, Tpeak to Tend and JT intervals indicate that the depolarization and/or 
repolarization is occurring more rapidly and efficiently [200-202]. Increased R amplitude suggests that 
the Piezo group exhibits a more uniform and concordant depolarization process since the ECG signal 
results from the sum of the several electrical signals originating from different points of the 
myocardium. These results not only point for a restoration of cardiac electrical integrity but also 
suggest that the Piezo group is less amenable to suffer ventricular arrhythmias [200-204]. However, 
this electrical conduction restoration did not reflect on significant improvements on systolic function, 
as assessed by transthoracic echocardiography. Nevertheless, the Piezo group presented tendencies 
to have improved fractional shortening and ejection fraction, while exhibiting a less dilated LV 
chamber. Curiously, the PCL group presented an increased (not statistical significant) cardiac output. 
The latter result might not necessarily imply improved cardiac function, since for equal ejection 
fractions, greatly dilated LV would present an increased cardiac output. The reasons behind the 
observed discrepancy between the echocardiography and the ECG results are unknown. However, it 
can be hypothesized that the piezoelectric fibers could have caused a more direct and rapid 
improvement on ventricular electrical conduction, while their impact on LV contractility and systolic 
function could be more progressive, causing relevant differences to be revealed only at later 
timepoints. This could be due to an effect similar to that of the primary electrical remodeling that can 
be defined as changes in the electrophysiological parameters of the heart that occur as a 
consequence of alterations in the natural order of electrical activation of the heart [205]. These 
alterations can induce, for instance, alterations in mechanical strain of the myocardium and, 
ultimately, alter its contraction patterns [205-208]. Furthermore, histological characterization showed 
no significant differences concerning infarct size and morphometric parameters (e.g LV free wall 
thickness), although LV dilation showed a tendency that corroborates with the echocardiographic 
findings (Figure 16).  
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Despite the fact that the piezoelectric fibers became physically isolated from the myocardium 
due to the foreign body reaction, a significant improvement of the cardiac electrical conduction was 
observed. It can be hypothesized that the charge accumulation that occurs on the piezoelectric fibers 
upon mechanical deformation could generate an electrical field with a sufficient range to electrically 
stimulate viable CMs in the periphery. In an attempt to maximize this putative effect of the fibers on 
the peripheral myocardial tissue, the Piezo patches were oriented in an oblique fashion upon its 
surgical placement so that most of the piezoelectric fibers would become parallel to the myocardial 
fibers [170, 209]. And, in fact, fiber orientation scoring revealed a clear tendency for the piezoelectric 
fibers to be oriented accordingly (Figure 15). However, even assuming that the fibers generated 
electrical fields with an almost optimal orientation, the exact mechanism through which these electrical 
stimuli induce improvements on ventricular conduction is unknown. We hypothesized that the Piezo 
patches could increase the amount of CMs near the implantation site that would, consequently, 
facilitate electrical conduction. However, histology revealed that the PCL group exhibited a higher 
proportion of CM islets within the infarcted zone Figure 16), disproving the hypothesis. In an attempt 
to unveil the mechanism, intercellular coupling was evaluated by analyzing the expression pattern of 
Cx43 (Figure 18), since it was observed an increase of functional Cx43 in the preliminary in vitro work 
involving these patches (unpublished data). However, no notable differences were detected between 
experimental groups. As it was observed in the preliminary in vitro work, the improvement of cardiac 
conduction could alternatively be explained by improved Ca2+ handling and/or increased expression 
of genes encoding for ionic channels subunits, such as alpha 1C (Cav1.2), and 1D (Cav1.3) subunits 
of L-type Ca2+ channels, Nav1.5, Kv7.1 and voltage-activated potassium channels (Kv11.1) (hERG), 
however the expression of said genes were not assessed in the herein work. It is known that cells 
react to changes on the biophysical properties of the surrounding microenvironment, which include 
electrical cues. Alterations on the surrounding electrical properties can instigate the occurrence of 
phenomena that can be transduced to biochemical signals, such as, for example: changes in 
membrane electrical charge, bound or release of ions from proteins, ion channel clustering in certain 
sites of the cell membrane and the activation of complex voltage-sensitive enzymes such as the 
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voltage-sensitive phosphatases (VSPs), which contain a voltage-sensitive domain that alters its 
conformation depending on the surrounding electrical field and that, by being attached to cytoplasmic 
phosphatase, it acts by dephosphorylating phosphoinositide phosphates (PIPs) that, in turn, can 
intervene in signaling pathways and alter cell phenotype and function [210-215]. 
To the best of our knowledge, previous studies that applied piezoelectric materials on the 
cardiovascular system have been only focusing on evaluating the beneficial effect of these materials 
on in vitro studies [216], being in vivo studies directed to energy harvesting by harnessing the 
movements originated from the cardiac cycle [217], which underline the novelty of the herein work. 
Despite no significant improvement on systolic function was observed, the results showed a 
marked ameliorating on electrical conduction. Although more thorough assessments should be 
performed on the present animal model, the results encourages one to scale-up this putative therapy 
for larger animal models and, eventually, for clinical application. However, note that larger animals 
and humans exhibit slower heart rates which, without an adequate scale-up, could hinder the electrical 
activity of the piezoelectric fibers. Since most novel therapies have been focusing on improving 
systolic function, LV remodeling and neovascularization (with promising results) (reviewed on [19, 
20]), rather than acting on cardiac conduction, therapeutic potential of the Piezo patches could be 
more efficiently harnessed if applied as a complementary therapy to the former, rather than being 
applied in an isolated manner. Additionally, in order to be successfully applied in a clinical 
environment, a more sterile and off-the-shelf formulation in association with less invasive patch 
placement procedure is advised. Moreover, considering the in vitro effect on CM maturation and 
intercellular coupling, the Piezo patches could be seeded with clinically relevant cells (e.g. iPSC or 
ESC-derived immature CMs) in a cardiac tissue engineering approach, promoting both ventricular 
conduction and, possibly, improved cell engraftment onto the native myocardium. 
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9. CONCLUSIONS 
The main goal of the herein work was to assess the therapeutic potential of biomaterial-based 
patches composed of PCL films and piezoelectric fibers on a murine model of MI. The successfully 
implanted patches triggered an exacerbated inflammatory response with characteristics which were 
typical of a foreign body reaction with piezoelectric fibers remaining detectable at 30 days after 
MI/patch implantation. Although ameliorations on systolic function and cardiac remodeling were not 
statistically significant (when compared to PCL-only controls), animals implanted with the Piezo 
patches exhibited improved cardiac conduction with evidences of having a reduced susceptibility to 
suffer ventricular arrhythmia events. These results support the therapeutic potential of Piezo patches, 
in particular, to restore electrical integrity restoration in heart failure scenarios. Moreover, herein in 
vivo results together with the previous biocompatibility studies (please see Preliminary Results) further 
anticipate the use of Piezo patches as conductive scaffolds for cardiac tissue engineering 
applications. 
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10. FUTURE PERSPECTIVES 
Despite the obtained evidences that Piezo patches demonstrate potential to improve 
outcome of MI, some methodological approaches may be improved and other parameters evaluated. 
To minimize the in vivo inflammatory response to the patch and avoid the observed foreign 
body response to Piezo patches, novel approaches such as biocompatible material coatings can be 
applied [198]. Moreover, alternatively to the use of the porcine fibrin glue, which is commercially 
available for research purposes, it should be considered the use of thrombin and fibrinogen isolated 
from murine plasma (as it is performed in humans for clinical applications). In line with this, as the 
putative foreign body cells were identified uniquely by their morphology and CD45 expression, the 
expression of, for instance, macrophage-related markers (e.g. CD68 [218]) are worth exploring. 
Moreover, it would be of interest to assess the composition of the macrophage compartment relatively 
to the M1 vs M2 phenotypes, since the latter exhibit anti-inflammatory properties [197, 218]. 
Regarding functional characterization, both echocardiographic and electrophysiological 
assessments should be performed on later timepoints in order to access the long-term effect of the 
Piezo patches. Relatively to the methodology, the analysis of electrophysiological parameters could 
be further insightful. For instance, surface ECGs should be measured at several timepoints or an 
ambulatory ECG monitoring system, allowing the analysis of isolated arrhythmic events which cannot 
be detected in a short time window [219]. Moreover, it would be useful to perform intracardiac 
electrograms for a more local electrophysiological assessment [75, 220] and/or Langerdoff perfusion 
system-associated ex vivo optical mapping [70, 151, 221] to understand whether Piezo patches affect 
conduction velocity and AP propagation of the myocardial tissue located near the infarcted zone. In 
addition, arrhythmia inducibility could be tested by means of, for instance, programmed electrical 
stimulation [74, 77]. 
In order to assess the mechanism through which the Piezo patches exert their beneficial 
effect, the transcriptional profile and protein expression of the CMs adjacent to the Piezo patches 
should be further explored by means of quantitative PCR and Western blot, respectively. This would 
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allow the assessment of not only the expression of the connexins and ionic channels (such as the 
ones that became overexpressed in the preliminary in vitro work) but also to assess if certain signaling 
pathways are altered in these CMs. For instance it would be interesting to explore alterations on the 
β1-integrin/ FAK/ERK/MEF-2c and GATA4 signaling pathway which influences Cx43 expression and 
that became altered in an in vitro study in that a conductive CNT-based material was used [145]. It 
would also be of interest to study the signaling pathways that could be influenced by VSP-mediated 
activity [210-215]. 
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